

IDMA BULLETIN

VOL. NO. 53

ISSUE NO. 12 (PAGES: 48)

22 TO 30 MARCH 2022

ISSN 0970-6054

WEEKLY PUBLICATION



Indian APIs & Formulations for Global Healthcare

INDIAN DRUG MANUFACTURERS' ASSOCIATION

IDMA Secretariat and
Editorial Team Wishes all our
Members and Readers



 **INDIAN DRUG MANUFACTURERS' ASSOCIATION**
SINCE 1961

 75
Azadi Ka
Amrit Mahotsav

www.idmaconclave.com
BLOCK YOUR DATES

14 & 15 APRIL 2022

INDIAN PHARMA - GLOBAL HEALTH CARE

Commemorating IDMA's Diamond Jubilee

2 Days | 25+ Speakers | 5 Panel discussions | 5+ Inspiring talks

Boundless Opportunities
To Be Future Ready
Atmanirbhar Bharat

#IDMA2022

LEARN NETWORK SHARE

An extraordinary platform showcasing accomplishments of the Indian Pharmaceutical Industry. An eclectic atmosphere to exchange ideas and insights with who's who from the industry. An exceptional opportunity to network with promoter leaders, c-suite professionals and investors. IDMA welcomes you to be a part of the history, relish the present and leapfrog into the future.

Hotel Sahara Star, Mumbai

KNOWLEDGE PARTNER
BAIN & COMPANY

 **DR. MANSUKH MANDAVIYA**
Hon'ble Minister of Health and Family Welfare and Chemicals and Fertilizers

 **SHRI PIYUSH GOYAL**
Hon'ble Minister of Commerce & Industry, Consumer Affairs, Food & Public Distribution and Textiles

GAIN IDEAS & INSIGHTS ON THE FUTURE OF PHARMA INDUSTRY IN INDIA

India's Role in Global Vaccine Development
Explore Opportunities for Private Equity Investments in Pharma Business
Understand How to Enhance Value from Manufacturing to Consumer
Inspiring Management lessons from Ancient Scriptures
Pharmaceutical Innovations in India
Roadmap for Positioning India as the Global API Hub

DO NOT MISS THE OPPORTUNITY TO INTERACT WITH VISIONARIES & CHANGEMAKERS

For more details write to actadm@idmaindia.com

No Spot
Registration
Register Now

HIGHLIGHTS

- ★ **Comprehensive Economic Partnership Agreement (CEPA) between India and the United Arab Emirates (UAE) unveiled** (Page No. 16)
- ★ **NITI Aayog Releases Second Edition of Export Preparedness Index 2021** (Page No. 17)
- ★ **Shanghai lockdown may choke pharma supplies** (Page No. 43)

UNWAVERING ATTENTION TO DETAIL. FOR ABSOLUTE **PRECISION.**

Dear Partner,

We are firm believers in partnering with those who make us stronger and add value to our customers. Partners such as Tereos and Biogrund who allow us to provide for even the most highly technical and specialised needs, with perfect precision.

Tereos is one of the world's leading sucrose producers, with expert products that allow for a wide variety of pharmaceutical applications. Over the last two decades, Biogrund has built itself as the specialists in top-quality solutions for oral dosage forms, such as film coating, tableting and colouration.

Together, we ensure that customers get exactly what they want, when they want it.

Signet-ure

Precision



- COMPRESSUC** (Directly Compressible Sucrose)
- ICING SUGAR** (Milled Sucrose)
- CASTER SUGAR** (Screened Sucrose)
- ALVEOSUCRE** (Agglomerated Sucrose)



- AQUAPOLISH** (Film Coating Systems)
- HME CLEANER PLUS** (Cleaning Agent for Hot Melt Extrusion)
- BONUWAX** (Ready-to-use Waxes)
- ISUPOLISH** (Sugar & Sugar-free Coating Systems)

Signet

The Complete Excipients Company



Founder Editor:
Dr. A. Patani

Editor:
Dr. Gopakumar G. Nair

Associate Editors:
Mr. J. L. Sipahimalani
Dr. Nagaraj Rao
Dr. George Patani

National President
Dr. Viranchi Shah

Immediate Past National President
Mr. Mahesh Doshi

Senior Vice-President
Mr. Bharat N Shah

Vice-Presidents:
Dr. George Patani
(Western Region)

Mr. Asheesh Roy
(Eastern Region)

Mr. B K Gupta
(Northern Region)

Mr. T Ravichandiran
(Southern Region)

Hon General Secretary
Mr. Mehul Shah

Hon Joint Secretaries
Mr. Kamlesh C Patel
Mr. Pranav Choksi

Hon Treasurer
Mr. Vinay Pinto

For information contact :
IDMA Secretariat: (H.O.)

Daara B Patel
Secretary-General

Melvin Rodrigues
Sr Manager (Commercial & Administration)

IDMA State Boards	Chairman
▶ Gujarat State Board	: Dr. Shrenik K Shah
▶ Haryana State Board	: P K Gupta
▶ Himachal Pradesh & Uttarakhand State Board	: R C Juneja
▶ Karnataka State Board	: S M Mudda
▶ Madhya Pradesh State Board	: Paresh Chawla
▶ Tamil Nadu, Puducherry & Kerala State Board	: J Jayaseelan
▶ Telangana State Board	: Shaik Janimiya
▶ West Bengal State Board	: Shiv Sagar Tewari
IDMA Delhi Office	: Ashok Kumar Madan Executive Director S. Ranganathan Asst. Manager (Administration)

A Publication of
Indian Drug Manufacturers' Association
102-B, 'A-Wing', Poonam Chambers,
Dr. A.B. Road, Worli, Mumbai - 400 018
Tel : 022-2494 4624 / 2497 4308 Fax: 022-2495 0723
e-mail: publications@idmaindia.com/
actadm@idmaindia.com/ website: www.idma-assn.org

Published on 7th, 14th, 21st and 30th of every month

Annual Subscription
₹ 1000/- (for IDMA members)
₹ 2000/- (for Government Research/Educational Institutions)
₹ 4000/- (for non-members) US\$ 400 (Overseas)
Please send your payment in favour of
Indian Drug Manufacturers' Association

OPINIONS EXPRESSED BY THE AUTHORS OF INDIVIDUAL ARTICLES
DO NOT NECESSARILY REPRESENT THE OFFICIAL VIEW OF IDMA.

IDMA BULLETIN

Vol. No. 53 Issue No. 12 22 to 30 March 2022

IDMA ACTIVITIES:

IDMA 60th Year Celebrations 2022.4
IDMA APTAR Innovation of the Year Award 2021.....7
IDMA thanks NPPA for extending date for increased price of Heparin
from 31/03/2022 to 30/09/2022 - reg..... 11

IDMA Congratulates the Winners of India Pharma World Awards 2022
Organised by EThealthworld.com and IDMA: India Pharma World
Summit on Technological Disruption in Pharma 2.0 held on 25th March 2022 12

Congratulations Mr Bhupendra Sangani, Managing Director & his team
at Galentic Pharma (India) Pvt. Ltd., for wining Quality Award for Excellent
Facility for the year 2021 at the OPPI Annual Submit held on 23rd March 2022 14

IDMA Congratulates our Members for being the Winners of ET Awards 14

GOVERNMENT PRESS RELEASE:

Comprehensive Economic Partnership Agreement (CEPA) between
India and the United Arab Emirates (UAE) unveiled 16

NITI Aayog Releases Second Edition of Export Preparedness Index 2021..... 17

DGFT MATTERS:

Amendment in Export Policy and insertion of Policy Condition
under Chapter 29 and 38 of ITC (HS), 2018 - reg..... 18

GOVERNMENT NOTIFICATIONS:

Draft Rules vide GSR No. 227(E), dt.29.3.2022 on Drugs
(...Amendment) Rules 2022- reg 20

INDIAN PHARMA COEPIA COMMISSION:

Report on 15th Regional Workshop on "Pharmacovigilance and Establishment
of Pharmacovigilance System in Pharmaceutical Industries – A Way
Forward" via Webinar on March 29, 2022 23

GOVERNMENT COMMUNICATIONS:

p-Xylene (Quality Control) Order, 2021 notified vide S.O. 3929(E),
dated the 13th September 2021 amended 24

Polyurethanes (Quality Control) Order, 2021 notified vide S.O. 3931(E),
dated the 13th September 2021 amended..... 24

India Pavilion at AFRICA HEALTH ExCon, Cairo, Egypt 5-7 June 2022 25

India Pavilion at KOREA PHARM South Korea, 14-17 June 2022..... 27

PARLIAMENT NEWS:

In Lok Sabha & In Rajya Sabha 29

NATIONAL NEWS:

Free trade agreements: Panel recommends FTA review
regime for mid-way corrections 41

India, UAE free trade agreement may come into force from May 1, says Goyal.... 41

US Pharmacopeia to invest in PCM lab in Genome Valley 42

Shanghai lockdown may choke pharma supplies..... 43

Local manufacturing of 35 APIs started after PLI scheme: Mandaviya 44

Dr Shrenik Shah elected chairman of IDMA Gujarat; plans three-pronged
strategy to boost Gujarat pharma sector 44

Obituary

IDMA mourns the Sad demise of our National President's
Father Shri Arvindbhai Hiralal Shah 15

IDMA mourns the Sad demise of Smt. Nirmalaben Shah,
Mother of Mr. Vijay Shah, Vice Chairman, IDMA GSB..... 15

Advertisements..... 2, 47 & 48



**INDIAN DRUG
MANUFACTURERS'
ASSOCIATION**
SINCE 1961



www.idmaconclave.com

BLOCK YOUR DATES

14 & **15** APRIL 2022

INDIAN PHARMA - GLOBAL HEALTH CARE



Commemorating IDMA's Diamond Jubilee

2
Days

25+
Speakers

5
Panel
discussions

5+
Inspiring
talks

Boundless Opportunities
To Be Future Ready
Atmanirbhar Bharat

#IDMA2022

LEARN NETWORK SHARE

An extraordinary platform showcasing accomplishments of the Indian Pharmaceutical Industry. An eclectic atmosphere to exchange ideas and insights with who's who from the industry. An exceptional opportunity to network with promoter leaders, c-suite professionals and investors. IDMA welcomes you to be a part of the history, relish the present and leapfrog into the future.

Hotel Sahara Star, Mumbai

KNOWLEDGE PARTNER
BAIN & COMPANY



CHIEF GUEST - INAUGURATION CEREMONY

DR. MANSUKH MANDAVIYA

Hon'ble Minister of Health and Family Welfare
and Chemicals and Fertilizers



CHIEF GUEST - VALEDICTORY CEREMONY

SHRI PIYUSH GOYAL

Hon'ble Minister of Commerce & Industry,
Consumer Affairs, Food & Public Distribution and Textiles

GAIN IDEAS & INSIGHTS ON THE FUTURE OF PHARMA INDUSTRY IN INDIA

India's Role in Global Vaccine Development

Explore Opportunities for Private Equity Investments in Pharma Business

Understand How to Enhance Value from Manufacturing to Consumer

Inspiring Management lessons from Ancient Scriptures

Pharmaceutical Innovations in India

Roadmap for Positioning India as the Global API Hub

DO NOT MISS THE OPPORTUNITY TO INTERACT WITH VISIONARIES & CHANGEMAKERS

For more details write to actadm@idmaindia.com



INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA) 1961 – 2021 (60 Glorious Years)

102, Poonam Chambers, A Wing, 1st Floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018. Maharashtra, India.

Tel: +91-22-24974308 / 24944624

Email: actadm@idmaindia.com Website: www.idma-assn.org

No Spot
Registration
Register Now

IDMA 60TH YEAR CELEBRATIONS 2022

Thursday, 14th & Friday, 15th April, 2022

Hotel Sahara Star, Mumbai

Dear Member,

Greetings from Indian Drug Manufacturers' Association (IDMA).

We are pleased to inform you that the IDMA 60th Year Celebrations is now scheduled for Thursday, 14th & Friday, 15th April 2022 at Hotel Sahara Star, Mumbai. We thank you for your co-operation and understanding with regards to the delay caused by the third wave of the Covid-19 pandemic and regret any inconvenience caused.

We, at IDMA, humbly request our Members to whole-heartedly participate in the IDMA 60th Year Celebrations by way of Registrations & Advertisements. Your support is very much desirable and necessary in strengthening your Association as well as for the success of any initiatives taken up by your Association. We are sure that with your support the 60th Year Celebrations is going to be a massive and glorious success story in the history of your Association.

We intend to commemorate this historic occasion of the completion of 60 years of our Association with a two days long celebration consisting of Panel Discussions, Technical Sessions and an Entertainment Program to boost the image of our Association as the Premier Association of the Indian Pharmaceutical Industry.

The goal of the Diamond Jubilee Celebrations is to:

- ❖ Showcase Pharmaceutical and Allied Industries across the Globe
- ❖ Disseminating knowledge on various subjects
- ❖ Highlighting the contribution of IDMA to bridge the gap between the Industry and the Ministry

This year at the 60th Year Celebrations, we have invited Eminent National and International personalities to address our members over two days. This event would be graced by Bureaucrats and Ministers from the Central Government as well as the State Government. The key torch bearers of the Pharmaceutical World would be an integral part of this event.

We are pleased to inform you that our Hon'ble **Dr. Mansukh Mandaviya**, Minister of Health & Family Welfare and Chemicals & Fertilizers has confirmed to be the Chief Guest at the Inaugural ceremony on 14th April 2022 and our Hon'ble **Shri Piyush Goyal**, Minister for Commerce & Industry, Consumer Affairs, Food & Public Distribution and Textiles has confirmed to be the Chief Guest at the Valedictory ceremony on 15th April 2022. **Dr. Gnanvatsal Swami Ji** will deliver a Spiritual Address on the 2nd Day. We have Industry Stalwarts who have confirmed their presence for various panel discussion scheduled over the two days, such as **Mr. Dilip Shanghvi** (Sun Pharmaceutical Industries), **Mr. Satish Reddy** (Dr. Reddy's Laboratories), **Dr. Amit Varma** (Quadria Capital), **Mr. Rakesh Jhunjunwala**, **Mr. Dhaval Shah** (PharmEasy), **Mr. K V Subramaniam** (Reliance Life Sciences), **Mr. Premchand Godha** (IPCA Laboratories) and **Mr. Rajeev Nanapaneni** (Natco Pharma).

We are pleased to inform you that **Bain & Co** is our knowledge partner for this event.

As part of the Celebrations, the winners of the:

1. IDMA Margi Patel Choksi Memorial Best Patent Awards
2. IDMA ACG-SCITECH Best Research Paper Awards
3. IDMA Corporate Citizen Awards
4. IDMA - N. I. Gandhi Chief Mentor Award

would be announced and the Awards would be presented.

Your Association has come a long way and many milestones have been achieved in the last 60 Years and specially the last two years which have been different, difficult and trying times. You would be pleased to note that during Covid-19 Pandemic, IDMA Secretariat has played an important role in facilitating uninterrupted supply of quality medicines with excellent coordination between the Industry, Government, Regulators and other Associations. Nevertheless, it is due to your untiring efforts and commitment to the wellbeing and prosperity of our Association that we will be completing 60 years of glorious service to our Pharma Industry and to our great Nation.

We are sure you will be an integral part of the Grand Celebrations.

IDMA 60th ANNUAL PUBLICATION 2022

The **IDMA 60th Annual Publication 2022**, an up-to-date and most informative compendium will be released at the Annual Celebrations. This Annual Publication will present statistics, vital data and information on the Pharmaceutical industry. This Publication has also come to be recognized as the indispensable reference book of the Indian Pharmaceutical Industry.

AN OFFER NOT TO BE MISSED

Advertisers can, through this single medium, reach their target audience such as Bulk Drug Manufacturers, Formulators, Researchers, Analysts, Traders, Scientists, Students, Consultants, various Government Officials etc. and leave an enduring impression on everyone connected with the Industry.

ADVERTISEMENT RATES		
SR. NO.	PARTICULARS	RATE PER ADVERTISEMENT (RS.)
1.	Double Spread	1,00,000
2.	Special Bookmark	1,00,000
3.	Full Page (Colour)	50,000
4.	Full Page (Black & White)	30,000

OPPORTUNITIES FOR SPONSORSHIPS:

We would be extremely pleased if you would accept one of the below Sponsorship for this celebrations :-

- PLATINUM SPONSOR : Rs.25 Lakh
- GOLD SPONSOR : Rs.10 Lakh
- DIAMOND SPONSOR : Rs.15 Lakh
- SILVER SPONSOR : Rs.5 Lakh

Sponsors will be provided special benefits & privileges as per the copy attached: For details please contact IDMA Secretariat.

REGISTRATION FEES:

To participate in the 60th Year Celebrations, the registration fee would be as under:

Reception Committee Member	–	Rs.7,500/- plus GST @ 18%
Delegate		Rs.6,000/- plus GST @ 18%

(For more than 4 registrations from one Company, the 5th registration will be complimentary)

For further details, please contact:

Mr. Melvin	Ms. Geeta	Ms. Batul	Ms. Parivaz
9821868758	9820161419	9920045226	9830081744
actadm@idmaindia.com	publications@idmaindia.com	technical@idmaindia.com	idma2@idmaindia.com

ROOM RATES :

We have negotiated Special Room Rates at Hotel Sahara Star for our members. The special room rate would be Rs.6,000/- + GST per night for a Single / Double Occupancy. The room rate includes complimentary breakfast and internet facilities.

Kindly note that those members who desire to stay at Hotel Sahara Star, please forward their details to the IDMA Secretariat.

Your active participation & interaction with the cream of the Pharmaceutical Industry as well as Ministry Officials and Bureaucrats, from the Centre as well as States, will not only add value to your business but also ensure that the flag of our Association continues to fly higher in the Global Pharmaceutical Industry.

Looking forward to your usual fine cooperation in making this historic event a 'सुपर से भी ऊपर' Success.

Thanking you,

With best regards,

Bharat Shah
Chairman, Organizing Committee,
IDMA 60th Year Celebrations

Dr. Viranchi Shah
National President

Daara B Patel
Secretary - General

IDMA - APTAR INNOVATION OF THE YEAR AWARD 2021

ATTENTION MEMBERS

Dear Members,

We are pleased to announce a New Award this year : **IDMA - APTAR INNOVATION OF THE YEAR AWARD 2021**.

We invite all IDMA members who have taken the initiative to innovate an exceptional product, service, device, etc. or having supported Innovations during the calendar year 2021 to participate.

Please note that only one award will be presented.

The Award function will be a part of the **IDMA's prestigious 60th Year Celebrations on Thursday, 14th & Friday, 15th April 2022 at Hotel Sahara Star, Near Domestic Airport, Vile Parle (East), Mumbai.**

For detailed Terms & Conditions please refer to the attached **IDMA - APTAR INNOVATION OF THE YEAR AWARD 2021 - Eligibility Criteria**. Entry Form is also attached for your early action. Please fill this form and send it to admin@idmaindia.com latest by **5th April 2022**.

For any queries, please feel free to connect with Ms. Sapna Patil (9619802299 / admin@idmaindia.com).

Looking forward to your prompt positive response.

With Best Wishes,

**Daara B. Patel
Secretary-General**

IDMA - APTAR INNOVATION OF THE YEAR AWARD 2021

(For IDMA Members Only)

NOMINATION FORM FOR PARTICIPANTS

Basic Information	:	
Name of Organization	:	
Name of the contact person	:	
Designation	:	
Contact Details	:	

Email ID	:	
Head Office Address	:	
Website URL	:	
Year of Incorporation	:	<i>(please attach the incorporation certificate)</i>
Mention the product/solution/device manufactured by your organization	:	
Elaborate the problem statement that led to the development of the innovation	:	
Describe the details innovation and how it addresses the problem	:	

Please submit the following	:	Launch Date	
		Cost of manufacturing	
		Implementation cost	
What is your Unique Selling Proposition	:		
Please describe the scalability of your product/solution/device	:		
Please describe your product/solution/device in terms of sustainability and its impact on the environment	:		
Please include picture/s of the innovation (in case of product/device).	:		
Why should you win this award?	:		

Authorized Signatory

Name of the Authorized Signatory : _____

Designation : _____

(please affix your company's stamp)

Eligibility Criteria

(For IDMA Members Only)

IDMA - APTAR Innovation of the Year Award 2021

Rules & Regulations

Definitions

- **Award management:** Indian Drug Manufacturers' Association (IDMA).
- **Award:** IDMA - APTAR INNOVATION OF THE YEAR AWARD 2021

For recognizing Innovations done by an IDMA member company in the area of innovative products, services, devices, etc. or having supported Innovations during the year.

- **Participant/ Nominee:** Any IDMA member company sending in their entry
- **Terms and conditions:** The terms and conditions governing the Awards.
- **Nominee/ Winner:** Award as decided by Jury.
- **Jury:** The jury to include office bearers/experts of IDMA & consultants with no business/personal interest in the nominated companies. The Jury will evaluate the entries and select final winners.

Timelines

The time lines for the awards are as follows:

- **Call for entries start date:** 23.03.2022
- **Last date for receiving entries:** 05.04.2022
- **Awards Function:** 14th & 15th April, 2022

Eligibility criteria

Only those meeting the following criteria may be eligible to be nominated.

- Applicant should be a member of IDMA.
- The final product/solution should be manufactured/implemented in India.
- The evaluation period is January 2021 – December 2021.
- To recognize companies which have been innovative (product, service, device, etc.) or have supported innovation during the year.
- The innovation must be adopted for commercial use after all regulatory clearances.

Winner determination

- The entries that are eligible will be evaluated by an independent panel of honorary jury members.
- The entry chosen as winner by the jury will be final and binding.
- Entries will be received on the specified email id by the Awards Management Team.
- Entries will be short listed based on eligibility criteria;
- Jury will select the winner based on predetermined judging parameters by scoring the entries.
- In case of a tie, more than 1 (one) winner will be declared.

Completeness of entries/ disqualification

- Ownership and integrity of information provided in the application solely rests with the applicant.
- Entries will be accepted in English language only.
- Please complete the form in permanent ink

- All questions marked with asterisk (*) must be answered. Incomplete entry form shall not be considered.
- Please write “NA” for the questions that you do not have answers to.
- Please be precise in your answers.
- The declaration must be signed by a senior employee of the organization (MD/Owner/Director/authorized signatory)
- The entry form may be submitted: By email to: admin@idmaindia.com
- The completed form must reach IDMA by: **5th April 2022**
- Please maintain one copy of the form for your records.
- If you have questions or require clarification, please contact: **Ms. Sapna Patil (9619802299)**.
- The final eligibility of the nominees is subject to the discretion and approval of the Jury.
- Information provided by the Applicants will be confidential and will be used only for the limited purpose of evaluating the entry to these Awards.
- Disqualification of any entries is at the sole discretion of the Jury/ Awards Management.
- All entries are subject to verification, including without limitation, verification of eligibility through checks as deemed appropriate by the Awards Management and complete compliance with these Terms and Conditions. Awards Management has the sole right to disqualify any entry if it is not in compliance with the Terms and Conditions herein specified or any further applicable laws, regulation/ or any policies that may be specified by the Awards Management.

Additional Information

- Participants may be contacted for any additional information to verify the information provided. Such additional information sourced from the Participant(s) will become part of the original application.
- Awards Management has the right to ask for documentary proof of information / audited financial data / review the information provided. If such a request is made and the Participant does not comply with it promptly; the Participant may be disqualified from participation in the Awards.
- Information provided by the Participant will be used only for the limited purpose of evaluating the Participant's entry to this Award and, for the specified purpose as agreed to.
- Awards Management or team appointed by Awards Management will try to contact the Participant on best effort basis by any means deemed appropriate.
- In the event it is not possible to contact any Participant to obtain information on them, interview them, etc. such Participant may be disqualified from further participation.
- Out-of-the-Box thinking: does this innovation represent out-of-the-box thinking? Scale of 1-10 (1-low, 10-high).
- Impact: will the innovation bring any change in the quality of life, way of working, safety, efficacy, etc for the user. Scale of 1-10 for each criteria (1-low, 10-high).
- Scalability: can this innovation be scaled up/replicated at an affordable cost Scale of 1-10 (1-low, 10-high).
- Numbers/rupee impact of the product.
- Does the innovation create a new market or change an existing market?
- Does the innovation meet an unmet need or create a new need?
- What is the immediate and long term impact of the innovation on the environment? Scale of 1-10 (1-low, 10-high)

Disclaimers

- Awards Management has no obligation to screen the entry material in advance, and is not responsible for monitoring entries for the purpose of preventing violation of intellectual property ownership rights, or violations of any law, rule or regulation. If Awards Management is notified of submissions or materials that may not conform to the Terms, it may investigate the allegation and determine in good faith and in its sole discretion whether to eliminate such an entry from consideration. The Awards Management has no liability or responsibility to Participants or other users of the Website for performance or non-performance of such activities.

IDMA thanks NPPA for extending date for increased price of Heparin from 31/03/2022 to 30/09/2022 - reg.

Dear Members,

This is with regards to IDMA representation submitted to Shri Kamlesh Kumar Pant, Chairman, National Pharmaceuticals Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, New Delhi dated 23rd March 2022 on request to extend revised ceiling prices of Heparin Injection fixed under Para 19 of DPCO-2013 (as reproduced below).

We are pleased to inform you that NPPA in its authority meeting held on 24th March 2022 have decided to extend the date for increased price of Heparin from 31/03/2022 to 30/09/2022. Minutes of the 228th (overall) and 96th Meeting of Authority under DPCO, 2013 held on 24.03.2022 are uploaded on NPPA website <https://www.nppaindia.nic.in/en/resources/authority-minutes/year-2021-2022/>. Interested Members can visit their website for complete information.

Respected Sir,

Greetings from Indian Drug Manufacturers' Association (IDMA).

Further to our letter dated 9th September 2021 with regards to the above mentioned subject, we sincerely thank you for your timely intervention & support to our members by issuing the Notification no. S.O. 3935(S) dated 23.09.2021 wherein the revised ceiling prices of Heparin Injection fixed under Para 19 of DPCO – 2013 were extended upto 31.03.2022.

Sir, IDMA on behalf of the Pharmaceutical industry appreciates your understanding of the ongoing concerns of exorbitant prices of Heparin Sodium ("API") which constitutes to be a quintessential portion of the input cost. NPPA by invoking its extraordinary powers in public interest issued a Notification no. S.O. 2151 (E) dated 30.06.2020 ("Notification") and increased the ceiling prices of Heparin Injection 10000IU/ml and Heparin Injection 5000IU/ml ("Product") by 50% which proved to be a saviour to many manufacturers of the said Product. Being an essential medicine for treatment in the ongoing pandemic situation, NPPA decided to continue with the increased ceiling price and the said Notification was extended vide another Notification no. S.O. 4333 (E) dated 03.12.2020 till 31.03.2021, Notification no. S.O. 1236 (E) dated 17.03.2021 till 30.09.2021 and further extended vide Notification no. S.O. 3935(S) till 31.03.2022.

IDMA has once again received several representations from the Pharmaceutical Industry requesting IDMA to

represent and request your good offices to extend the validity of the revised ceiling price of the Product beyond the notified period i.e. 31.03.2022 so as to sustain themselves during the ongoing pandemic situation. The said Product has proved to be an essential treatment in the ongoing pandemic situation. Apart from being an essential treatment in the Covid-19 scenario, the Product still remains the front line drug and lifesaving drug used for dialysis in case of kidney failure. This in turn has resulted in a higher demand for the Product.

Pertinently, it was only due to NPPA's thoughtful step of granting extension of revised ceiling price of the Product that enabled the manufacturers to put up with such high demand.

It would be relevant to note that the issue of high prices of API continues to haunt the manufacturers of the Product due to which many of the manufacturers are unable to sustain in this particular scenario where the demand of the Product is equally high. Besides, many of the manufacturers of the Product are still operating at a huge loss to manufacture and supply the Product due to the continuing increase in the import price of API imported from China.

Needless to mention that the pandemic has brought extreme hardship to the entire industry and the impact of the pandemic situation is anticipated to stay in the market for some time before the situation moves towards normalcy.

As an association, we believe that striking a balance between the availability of the Product and extending

requisite support to the manufacturers is the panacea for ensuring the well-being of our population.

Therefore, in order to ensure consistent availability of the Product in a scenario where the demand for the Product, as well as the prices of API from China are also high, there is a dire need to extend the revised ceiling price of the Product beyond 31.03.2022 till **31st March 2023** or till a time considered suitable in the present scenario.

Thanking you and assuring you of our best attention at all times.

Yours sincerely,


For Indian Drug Manufacturers' Association,

Dr Viranchi Shah
National President



IDMA Congratulates the Winners of India Pharma World Awards 2022 Organised by ETHealthworld.com and IDMA: India Pharma World Summit on Technological Disruption in Pharma 2.0 held on 25th March 2022

Congratulations BDR Pharmaceuticals International Pvt. Ltd., On being awarded with API Company of the Year and Excellence in Research Based on Data & Insights



Congratulations Dr Sharvil Patel, MD, Zydus Lifesciences Ltd., On being awarded with Pharma Leader of the Year and Excellence in CSR



Congratulations Lupin Ltd., On being awarded with Marketing Campaign of the Year



The Distinguish Jury:



Congratulations Mr Bhupendra Sangani, Managing Director & his team at Galentic Pharma (India) Pvt. Ltd., for wining Quality Award for Excellent Facility for the year 2021 at the OPPI Annual Submit held on 23rd March 2022



IDMA Congratulates our Members for being the Winners of ET Awards



Congratulations Mr Adar Poonawala, CEO, Serum Institute of India (SII), on being awarded with ET Business Leader of the Year 2021




Congratulations Dr. Satyanarayana Chava, Founder & CEO, Laurus Labs, on being awarded with ET Emerging Company of the Year 2021



OBITUARY

IDMA mourns the Sad demise of our National President's Father Shri Arvinbhai Hiralal Shah



We are deeply saddened to inform you of the sad demise of Shri Arvinbhai Hiralal Shah founder of Saga lifesciences Ltd, Saga Laboratories and Saga Healthcare Pvt Ltd and Father of Dr Viranchi Shah, National President, IDMA. He departed for his heavenly abode on Wednesday, 23rd March 2022.



IDMA mourns the Sad demise of Smt. Nirmalaben Shah, Mother of Mr. Vijay Shah, Vice Chairman, IDMA GSB



We are deeply saddened to inform you of the sad demise of Smt. Nirmalaben Shah, Mother of Mr. Vijay Shah, Vice Chairman, IDMA GSB and Managing Director of Stallion Laboratories Pvt. Ltd. She departed for her heavenly abode on Monday, 21st March 2022.



Comprehensive Economic Partnership Agreement (CEPA) between India and the United Arab Emirates (UAE) Unveiled

Unveiling of Indo-UAE CEPA is Historic day in India UAE ties - Shri Goyal

CEPA to Benefit both the countries in big way-Shri Goyal

Shri Piyush Goyal, Union Minister of Commerce and Industry, Consumer Affairs, Food and Public Distribution, and Textiles, Government of India, today announced the unveiling of the Comprehensive Economic Partnership Agreement (CEPA) between India and the United Arab Emirates (UAE) at a press conference held on 28 March 2022 during his visit to the United Arab Emirates. Shri Goyal is in UAE to participate in 'Investopia Summit' and 'World Government Summit' being held in Dubai on 28th March 2022 and 29th March 2022 respectively. With this launch, the text of the India-UAE CEPA is now available in public domain.

India-UAE CEPA was signed on 18 February 2022 in New Delhi during the India-UAE Virtual Summit held between His Excellency Shri Narendra Modi, Hon'ble Prime Minister of India and His Highness Sheikh Mohammed Bin Zayed Al-Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and Chairman of the Executive Council.

The salient features of India-UAE CEPA are as follows:

The India-UAE CEPA is the first deep and full free trade Agreement to be signed by India with any country in the past decade. The Agreement is a comprehensive agreement, which will cover Trade in Goods, Rules of Origin, Trade in Services, Technical Barriers to Trade (TBT), Sanitary and Phytosanitary (SPS) measures, Dispute Settlement, Movement of Natural Persons, Telecom, Customs Procedures, Pharmaceutical products, Government Procurement, IPR, Investment, Digital Trade and Cooperation in other Areas.

Impact or benefits:

CEPA provides for an institutional mechanism to encourage and improve trade between the two countries.

The CEPA between India and the UAE covers almost all the tariff lines dealt in by India (11,908 tariff lines) and the UAE (7581 tariff lines) respectively. India will benefit from preferential market access provided by the UAE on over 97 % of its tariff lines which account for 99% of Indian exports to the UAE in value terms, especially for all labour-intensive sectors such as Gems and Jewellery, Textiles, leather, footwear, sports goods, plastics, furniture, agricultural and wood products, engineering products, medical devices, and Automobiles. India will also be offering preferential access to the UAE on over 90% of its tariff lines, including lines of export interest to the UAE.

As regards trade in services, India has offered market access to the UAE in around 100 sub-sectors, while Indian service providers will have access to around 111 sub-sectors from the 11 broad service sectors such as 'business services', 'communication services', 'construction and related engineering services', 'distribution services', 'educational services', 'environmental services', 'financial services', 'health related and social services', 'tourism and travel related services', 'recreational cultural and sporting services' and 'transport services'.

Both sides have also agreed to a separate Annex on Pharmaceuticals to facilitate access of Indian pharmaceutical products, especially automatic registration and marketing authorisation in 90 days for products meeting specified criteria.

Timelines:

The negotiations for India-UAE CEPA were concluded in a record span of 88 days. The Agreement is expected to enter into force on 01 May 2022.

Background:

India and the UAE enjoy excellent bilateral relations, which are deep rooted and historical, sustained and

nurtured by close cultural and civilizational affinities, frequent high-level political interactions, and vibrant people to people linkages. The India-UAE comprehensive strategic partnership initiated during the visit of Prime Minister of India to UAE on 16-17 August 2015, is the cornerstone of our multi-faceted bilateral relations.

Growing India-UAE economic and commercial relations contribute to the stability and strength of a rapidly diversifying and deepening bilateral relationship between the two countries. India and the UAE have been each other's leading trading partners. These excellent bilateral economic and commercial relations have continued to enhance and deepen over time. From US\$ 180 million per annum in the 1970s, India-UAE bilateral trade has steadily increased to US\$ 60 billion (₹4.55 lakh crore) in FY 2019-20 making the UAE, India's third largest trading partner. With exports to the UAE valued at US\$ 29 billion for the year 2019-20, the UAE is also the second largest export destination of India, while Indian imports from the UAE were valued around US\$ 30 billion, including 21.83 MMT (US\$ 10.9 billion) of crude oil. The UAE is an important

source of India's energy supply and a key partner of India in the development of strategic petroleum reserves, upstream, and downstream petroleum sectors.

The UAE is also the eight largest investor in India with an estimated investment of US\$ 18 billion. Moreover, India and the UAE have recently entered into a Memorandum of Understanding (MoU) whereby the UAE has committed US\$ 75 billion towards infrastructure development in India. Further, in October 2021, Government of Dubai signed an MoU with the Jammu and Kashmir administration for real estate development, industrial parks, IT towers, multipurpose towers, logistics, medical college, super specialty hospital and more.

The India-UAE CEPA will further cement the already deep, close and strategic relations between the two countries and will create new employment opportunities, raise living standards, and improve the general welfare of the peoples of the two countries.

Source: PIB Delhi, 27.03.2022



NITI Aayog Releases Second Edition of Export Preparedness Index 2021

Most of the Coastal States are the best performers.

Gujarat ranked No. 1 for the second time in a row.

NITI Aayog, in partnership with the Institute of Competitiveness, released the Export Preparedness Index (EPI) 2021 today.

The report is a comprehensive analysis of India's export achievements. The index can be used by states and union territories (UTs) to benchmark their performance against their peers and analyse potential challenges to develop better policy mechanisms to foster export-led growth at the subnational level.

The Export Preparedness Index is a data-driven endeavour to identify the fundamental areas critical for subnational export promotion.

The EPI ranks states and UTs on 4 main pillars—Policy; Business Ecosystem; Export Ecosystem; Export

Performance—and 11 sub-pillars—Export Promotion Policy; Institutional Framework; Business Environment; Infrastructure; Transport Connectivity; Access to Finance; Export Infrastructure; Trade Support; R&D Infrastructure; Export Diversification; and Growth Orientation.

The index was released by NITI Aayog Vice Chairman Dr Rajiv Kumar, in the presence of NITI Aayog CEO Amitabh Kant, Department of Commerce Secretary BVR Subrahmanyam, and other dignitaries.

This edition has shown that most of the 'Coastal States' are the best performers, with Gujarat as the top performer.

EPI 2021 brings out three major challenges to India's export promotion. These are intra- and inter-regional differences in export infrastructure; weak trade support and growth orientation across states; and lack of R&D infrastructure to promote complex and unique exports.

The EPI's primary goal is to instil competition among all Indian states ('Coastal', 'Landlocked', 'Himalayan', and 'UTs/City-States') to bring about favourable export-promotion policies, ease the regulatory framework to prompt subnational export promotion, create the necessary infrastructure for exports, and assist in identifying strategic recommendations for improving export competitiveness. It promotes competitive federalism and a fair contest among States/UTs.

The index can be a valuable tool for the government and policymakers in encouraging healthy competition among states and UTs, hence enhancing India's standing in the global export market.

While releasing the report, NITI Aayog Vice Chairman Dr Rajiv Kumar remarked that EPI 2021 will help the

states and UTs in a long way to plan and execute sound export-oriented policies for ensuring a conducive export ecosystem, to make maximum utilization of their export potential.

NITI Aayog CEO Amitabh Kant emphasized that the second edition of the index will be a significant catalyst for promoting competitive federalism and a fair contest among states and UTs in the global export landscape.

During the event, Department of Commerce Secretary B.V.R. Subrahmanyam highlighted that there is also a need to work continuously on strengthening our manufacturing and infrastructure ecosystems at the state/UT levels to ensure robust growth of exports in the future.

Source: PIB Delhi, 25.03.2022



DGFT MATTERS

Amendment in Export Policy and insertion of Policy Condition under Chapter 29 and 38 of ITC (HS), 2018 - reg.

DGFT Notification No.62/2015-2020, dated 23rd March, 2022

- In exercise of powers conferred by Section 3 read with Section 5 of the Foreign Trade (Development and Regulation) Act, 1992 (as amended from time to time) read with paragraph 1.02 and 2.01 of the Foreign Trade Policy, 2015-2020, the Central Government hereby makes amendment in the Export Policy of Chapter 29 and 38, ITC (HS), Export Policy, 2018, for the following HS codes as under:

Sr. No.	HS Code	Item Description	Present Export Policy	Revised Export Policy
151 A	29034100	Trifluoromethane (HFC-23)	Free	Restricted
151 B	29034200	Difluoromethane (HFC-32)	Free	Restricted
151 C	29034300	Fluoromethane (HFC-41), 1,2-difluoroethane (HFC- 152) and 1,1-difluoroethane (HFC- 152a)	Free	Restricted
151 D	29034400	Pentafluoroethane (HFC-125), 1,1,1- trifluoroethane (HFC-143a) and 1,1,2- trifluoroethane (HFC-143)	Free	Restricted
151 E	29034500	1,1,1,2- Tetrafluoroethane (HFC-134a) and 1,1,2,2- tetrafluoroethane (HFC-134)	Free	Restricted
151 F	2903 46 00	1,1,1,2,3,3,3-Heptafluoropropane (HFC- 227ea), 1,1,1,2,2,3-hexafluoropropane (HFC- 236cb), 1,1,1,2,3,3-hexafluoropropane (HFC- 236ea) and 1,1,1,3,3,3-hexafluoropropane (HFC-236fa)	Free	Restricted

151 G	2903 47 00	1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,2,2,3-pentafluoropropane (HFC- 245ca)	Free	Restricted
151 H	2903 48 00	1,1,1,3,3-Pentafluorobutane (HFC-365mfc) and 1,1,1,2,2,3,4,5,5,5-decafluoropentane (HFC-43- 10mee)	Free	Restricted
151 I	290351 00	2,3,3,3- Tetrafluoropropene (HFO-1234yf), 1,3,3,3-tetrafluoropropene (HFO1234ze) and (z)- 1,1,1,4,4,4-hexafluoro-2-butene (HFO-1336mzz)	Free	Restricted
151 J	382751 00	Containing trifluoromethane (HFC-23)	Free	Restricted
151 K	382759 00	Other - Containing other Hydrofluorocarbons (HFCs) but not containing chlorofluorocarbons (CFCs) or hydrochlorofluorocarbons (HCFCs)	Free	Restricted
151 L	3827 61 00	Containing 15% or more by mass of 1,1,1 - trifluoroethane (HFC -143a)	Free	Restricted
151 M	3827 62 00	Other, not included in the sub -heading above, containing 55% or more by mass of pentafluoroethane (HFC -125) but not containingunsaturated fluorinated derivatives of acyclic hydrocarbons (HFOs)	Free	Restricted
151 N	3827 63 00	Other, not included in the sub -headings above, containing 40% or more by mass of pentafluoroethane (HFC -125)	Free	Restricted
151 O	3827 64 00	Other, not included in the sub -headings above, containing 30% or more by mass of 1,1,1,2 - tetrafluoroethane (HFC -134a) but not containing unsaturated fluorinated derivatives of acyclic hydrocarbons (HFOs)	Free	Restricted
151 P	3827 65 00	Other, not included in the sub -headings above, containing 20% or more by mass of difluoromethane (HFC -32) and 20% or more by mass of pentafluoroethane (HFC -125)	Free	Restricted
151 Q	3827 68 00	Other, not included in the sub-headings above, containing substances of subheadings 29034100 to 29034800	Free	Restricted

2. A new policy condition no.1 is incorporated in Chapter 29 and 38 respectively of ITC (HS), Schedule – 2 (Export Policy).

“Export of Hydrofluorocarbons (HFCs) is permitted with an Export authorization subject to NOC of Ozone Cell, MoEF&CC”.

Effect of this Notification

Export Policy of Hydrofluorocarbons (HFCs) has been revised from ‘Free’ to ‘Restricted’ category with immediate effect and export Authorisations would be issued based on NOC from MoEF&CC.

S.O.1270(E) F.No.01/91/180/028/AM22/EC /E-30957

Santosh Kumar Sarangi, Director General of Foreign Trade, Ex-Officio Addl. Secretary, Ministry of Commerce and Industry, Department of Commerce, Directorate General of Foreign Trade, New Delhi.



Draft Rules vide GSR No. 227(E), dt.29.3.2022 on Drugs (....Amendment) Rules, 2022- reg.

G.S.R. 227(E), dated 29th March, 2022

Dear Member,

This is with regards to Ministry of Health & Family welfare notification on Draft Rules vide GSR No. 227(E), dt.29.3.2022 on Drugs (....Amendment) Rules 2022.

Members are requested to send their Suggestions / Objections comments within 30 days.

Objections and suggestions which may be received from any person within the period specified above will be considered by the Central Government; Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 434, C Wing, Nirman Bhavan, New Delhi - 110011 or emailed at drugsdiv-mohfw@gov.in.

The following draft of certain rules further to amend the Drugs Rules, 1945, which the Central Government proposes to make, in exercise of the powers conferred by sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), is hereby published after consultation with the Drugs Technical Advisory Board for information of all persons likely to be affected thereby and notice is hereby given that the said draft rules shall be taken into consideration on or after the expiry of a period of thirty days from the date on which copies of the Gazette of India containing these draft rules are made available to public;

Objections and suggestions which may be received from any person within the period specified above will be considered by the Central Government;

Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 434, C Wing, Nirman Bhavan, New Delhi - 110011 or emailed at drugsdiv-mohfw@gov.in.

DRAFT RULES

1. (1) These rules may be called the Drugs (.....Amendment) Rules, 2022.
- (2) These rules shall come into force on the date of their final publication in the Official Gazette.
2. In the Drugs Rules, 1945, in rule 127, in sub-rule (1), for the existing Proviso, the following Proviso shall be substituted, namely:—

"Provided that in case of disinfectants, in addition to the above said colours, the colours referred in IS 4707 (Part I) as amended by Bureau of Indian Standards from time to time and any of the colours which is non-staining specified below shall be permissible to use.

Common name of the colour	Colour Index Number	Chemical name of the colour
1	2	3
Guinea Green B	42085	Monosodium salt of 4-(N-ethyl-p- sulfobenzylamino)-diphenylmethylone-(1-(N-ethyl-N-p- sulfoniumbenzyl) 2,5-cyclohexadienimine).
Light Green SF Yellowish	42095	Disodium salt of 4-[4-(N-ethyl-p-sulfobenzylamine)- phenyl]-4-sulphoniumphenyl) methylene]-2-(N-ethyl- N-sulfobenzyl) 2,5-Cyclohexadienimine.
Tartrazine	19140	Trisodium salt of 3-carboxy-5-hydroxy-1-p- sulfophenyl-4-p-sulfophenylazo-pyrazole.

Sunset yellow FCF	15985	Disodium salt of 1-p-sulfophenylazo-2-naphthol-6-sulfonic acid.
Ponceau 3R	16155	Disodium salts of a mixture of 1-alkyl-phenylazo-2-naphthol 3, 6-disulfonic acids.
Amarnath	16185	Trisodium salt of 1-(4-sulfo-1-naphthylazo)-2-naphthol 3, 6-disulfonic acid.
Erythrosine	45430	Disodium salt of 9-O-carboxyphenyl-6-hydroxy 2,4,5, 7-tetraiodo-3-isoxanthone.
Ponceau SX	14700	Disodium salt of 2-(5-sulfo-2, 4-xylyl-azo)-1-naphthol-4-sulfonic acid.
Brilliant Blue FCF	42090	Disodium salt of 4-(9-4-(N-ethyl-p-sulfobenzylamino)-phenyl)-2-sulfonium phenyl-methylene)-(1-(N-ethyl-N-p-sulfobenzyl)-2, 5-cyclohexadienimine).
Indigocarmine	73015	Disodium salt of 5,5'-indigotindisulfonic acid.
Wool Violet 5 BN (Acid-violet 6B)	42640	Monosodium salt of 4-(N-ethyl-p-sulfobenzylamino)-phenyl)-(4-(N-ethyl-p-(sulfonium-benzylamine)-phenyl)methylene)-(N,N-dimethyl-2,5-cyclohexadienimine)
Light Green SF Yellowish	42095	Calcium salt of 4-(4-(N-ethyl-p-sulfobenzyl) (minophenyl) (4-sulfonium-phenyl)methylene), (1-(N-ethyl-N-p-sulfobenzyl)-2,5-cyclohexadienimine).
Alizarin Cyanine Green F	61570	Disodium salt of 1,4-bis(O-sulfo-p-toluino) anthraquinone
Quinazarine Green SS	61565	1,4-bis-(p-Toluino)-anthraquinone
Fast Green FCF	42053	Disodium salt of 4-(4-(ethyl-p-sulfobenzylamino)-phenyl) (4-hydroxy-2-sulphoniumphenyl)methylene)-(1-N-ethyl-N-p-sulfobenzyl) 2, 5, cyclohexadienimine).
Acid Fast Green	42100	Monosodium salt of 4-(4-N-ethyl-p-sulfobenzylomino phenyl)-(o-chlorophenyl)-methylene)-1-(N-ethyl-N-p-sulfonium benzyl-2,5, cyclohexadienimine).
Pyranine Concentrated	59040	Trisodium salt of 10-hydroxy-3,5,8-pyrene-trisulfonic Acid
Quinoline Yellow WS	47005	Disodium indandione.
Quinoline Yellow SS	47000	2-(2-quinolyl)-1, 3 indandione.
Poneceau 2 R	16150	Disodium salt of 1-xylylazo-2-naphthol-3, 6-disulfonic acid.
Lithol Rubin B	15850	Monosodium salt of 4-(o-sulfo-p-tolylazo)3 hydroxy-2-naphthoic acid.
Lithol Rubin BCA	15850	Calcium salt of 4-(o-sulfo-p-tolylazo)-3-hydroxy-2-naphthoic acid
Lake Red D	15500	Monosodium salt of 1-O-carboxyphenylazo-2-naphthol.
Lake Red DBA	15500	Barium salt of 1-o-carboxyphenylazo-2-naphthol.
Lake Red DCA	15500	Calcium salt of 1-o-carboxyphenylazo-2-naphthol.
Toney Red	26100	1-p-phenylazophenylazo-2-naphthol.
Oil Red OS	26125	1-Xylylazoxylylazo-2-naphthol
Tetrabromofluorescein	45380	2,4,5,7-Tetrabromo-3, 6-fluorandiol.
Eosin TS	45380	Disodium salt of 2,4,5,7-tetrabromo-9-O carboxyphenyl-6-hydroxy-3-isoxanthone.
Eosin YSK.	45380	Dipotassium salt of 2,4,5,7-tetrabromo-9-O carboxyphenyl-6-hydroxy-3-isoxanthone
Tetrachlorofluorescein NA	45366	2,4,5,7-tetrachloro-S, 6-Fluorandiol
Tetrachlorofluorescein K	45366	Disodium salt of 9-O-carboxyphenyl-2,4,5,7-tetrachloro-6-hydroxy-3-isoxanthone.
Tetrachloro Tetrabromo fluorescein	45410	2,4,5,7-Tetrabromo-12,13,14,15-tetrachloro-3, 6-fluorandiol.
Phloxine B	45410	Disodium salt of 2,4,5,7-tetrabromo-9(3,4,5,6-tetra chloro-o-carboxyphenyl)-6-hydroxy-3-isoxanthone
Bluish Orange T.R.	45457	1,4,5,8, 15-Pentabromo-2, 7-dicarboxy-3, 6-fluoran diol.
Helindone Pink CN	73360	5, 5-Dichloro-3, 3' dimethyl-thioindigo
Deep Maroon (Fanchon Maroon)	15880	Calcium salt of 4-(1-sulfo-2-naphthylazo 3-hydroxy-2-naphthoic acid.

Toluidine Red	12120	1-(o-Nitro-p-tolylazo)-2-naphthol.
Flaming Red	12085	l- (o-Chloro-p-nitrophenylazo)-2-naphthol
Deep Red (Maroon)	12350	3-Hydroxy-N- (m-nitrophenyl)-4-(o-nitro-p-tolylazo)-2-naphthamide.
Alba Red	13058	o-(p,β,β-Dihydroxy-diethylamino)- phenylazo)-benzoic acid.
Orange G	16230	Disodium salt of 1-phenylazo-2-naphthol-6-8-disulfonic acid
Orange II	15510	Monosodium salt of 1-p-sulfophenylazo-2-naphthol.
Dichlorofluorescein	45365	4,5-Dichloro-3, 6-fluorandiol.
Dichlorofluorescein NA	45365	Disodium salt of 9-o-carboxyphenyl-1-4,5- dichloro-6-hydroxy-3-isoxanthone
Diiodofluorescein	45425	4,5 –Diiodo-3, 6-fluorandiol
Erythrosine Yellowish NA	45425	Disodium salt of 9-o-carboxyphenyl-6- hydroxy-4, 5- diiodo-3-isoxanthone.
Erythrosine Yellowish K	45425	Dipotassium salt of 9-o-carboxyphenyl-6-hydroxy-4, 5-diiodo-3-isoxanthone.
Erythrosine Yellowish NH	45425	Dipotassium salt of 9-o-carboxyphenyl-6-hydroxy-4, 5-diiodo-3-isoxanthone
Orange TR	45456	4,5, 15-Tribromo 2, 7-dicarboxy-3, 6- fluorandiol.
Alizarin	58000	1,2- Anthraquinonediol.
Dibromodiodofluorescein	45371	4,5- Dibromo-2, 7-diiodo-3, 6-fluorandiol.
Alphazurine FG	42090	Diammonium salt of 4-(N-ethyl-p- sulfobenzyl amino)-phenyl)-(2-sulfoniumphenyl)-Methylene)-(1 (N-ethyl-N- p- sulfobenzyl) 2 ,5-cyclohexadienimine).
Allarin Astrol B	61530	Monosodium salt of 1-methylamino-4-(o-sulfo-p-toluino)-anthroquinone.
Indigo	73000	Indigotin.
Patent Blue NA	42052	Monosodium salt of 4-(4- (N-ethyl- benzyl-amino)-phenyl – (5-hydroxy-4-sulfo-2-sulfoniumphenyl-methylene)(N-ethyl-Benzyl- 2, 5-cyclohexadienimine).
Patent Blue CA	42052	Calcium salt of 4-(4- (N-ethyl- benzyl-amino)-phenyl)-(5 hydroxy-4-sulfo-2-sulfoniumphenyl, methylene)- (N-ethyl- N-benzyl- 2- 5-cyclohexadienimine).
Carbrantherene Blue	69825	3, 3- Dichloroindanthrene.
Napthol Blue Black	20470	Disodium salt of 8-amino-7-p- nitrophenylazo 3- phenylazo-1- naphthol-3, 6-disulfonic acid
Alizuroi purple SS	60725	l-hydroxy-4-p-toluino-anthraquinone.
Acid Red 89	23910	----
Acid Red 97	22890	----
Acid Blue 1	42045	----
Food Blue 3	42045	----
Natural Orange	75480	----
Solvent Blues 4	44045	----
Solvent Yellow 18	12740	----
Food Yellow 12	12740	----
Solvent Yellow 32	48045	----
Fanchon Yellow (Hansa Yellow G)	11680	() -(O-Nitro-p-tolylazo) accetoacetanilide


F. No. X.11014/14/2021-DR

Dr. Mandeep K Bhandari, Joint Secretary, Ministry of Health and Family Welfare, Department of Health and Family Welfare, New Delhi.

Note: The principal rules were published in the Official Gazette vide notification No. F.28-10/45-H(1), dated 21st the December, 1945 and last amended vide notification number G.S.R.....(E), dated the



Report on 15th Regional Workshop on “Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries – A Way Forward” via Webinar on March 29, 2022



Participants from 15th Regional Workshop on “Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries – A Way Forward”

The Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India has organized **15th Regional Workshop on “Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries– A Way Forward”** via webinar on March 29, 2022. The workshop was tailored to regional needs and addressed challenges unique to Pharmacovigilance (PV) and its setup in Pharmaceutical industries. The workshop also addressed the basic concepts of PV & how the PV system can be effectively implemented by the MAHs in Pharmaceutical Industries and also to make them aware about the PV Guidance Document with the major focus on submission of E2B XML ADR related files to PvPI. The workshop was initiated with opening remarks by **Dr. Jai Prakash**, Sr. Principal Scientific Officer, IPC & Officer in-charge, PvPI & keynote address by

Dr. Rajeev Singh Raghuvanshi, Secretary cum-Scientific Director, IPC. On behalf of National Coordination Centre for Pharmacovigilance Programme of India, **Dr. Shashi Bhushan**, **Mr. Rishi Kumar**, **Ms. Swati Thapliyal** & **Ms. Bhanu Priya** were present in the workshop. More than 35 participants from different pharmaceutical industries and research institutes participated in this workshop. **Dr. Jai Prakash**; **Dr. Rubina Bose**, Deputy Drugs Controller (I), CDSCO, (HQ) & Ms. Sudha Sharma, Pharmacovigilance Assistant, Wipro GE Healthcare Private Limited, India & Ms. Nidhi Vaish Das, Manager Drug Safety, Roche Products (India) Private Limited, deliberated on topics related to PV. The MAHs assured that they would effectively implement the PV system and train their colleagues in their organization.

Note: Please visit our website (www.ipc.gov.in) for regular updates.

p-Xylene (Quality Control) Order, 2021 notified vide S.O. 3929(E), dated the 13th September 2021 amended

Chemicals & Fertilizers Order S.O.1276(E), dated 23rd March 2022

In exercise of the powers conferred by section 16 read with sub-section (3) of section 25 of the Bureau of Indian Standards Act, 2016 (11 of 2016), the Central Government, after consulting the Bureau of Indian Standards is of the opinion that it is necessary or expedient so to do in the public interest, hereby makes the following Order to amend the p-Xylene (Quality Control) Order, 2021, namely:-

1. Short title and commencement :

- (1) This Order may be called the **p-Xylene (Quality Control) Order, 2022.**
- (2) It shall come into force on the date of its publication in the Official Gazette.

2. In the p-Xylene (Quality Control) Order, 2021, in paragraph 1, for sub-paragraph (2), the following sub-paragraph shall be substituted, namely:-

“(2) It shall come into force on the 19th September, 2022.”

F. No. PC-II 46016/ 6/2020-Tech.CPC Pt-2

Kashi Nath Jha, Joint Secretary, Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers, New Delhi.

Note: The principal Order was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), vide number S.O.3929(E), dated the 13th September, 2021



Polyurethanes (Quality Control) Order, 2021 notified vide S.O. 3931(E), dated the 13th September 2021 amended

Chemicals & Fertilizers Order S.O.1277(E), dated 23rd March 2022

In exercise of the powers conferred by section 16 read with sub-section (3) of section 25 of the Bureau of Indian Standards Act, 2016 (11 of 2016), the Central Government, after consulting the Bureau of Indian Standards is of the opinion that it is necessary or expedient so to do in the public interest, hereby makes the following Order to amend the Polyurethanes (Quality Control) Order, 2021, namely:-

1. Short title and commencement

- (1) This Order may be called the **Polyurethanes (Quality Control) Order, 2022.**
- (2) It shall come into force on the date of its publication in the Official Gazette.

2. In the Polyurethanes (Quality Control) Order, 2021, in paragraph 1, for sub-paragraph (2), the following sub-paragraph shall be substituted, namely:-

“(2) It shall come into force on the 19th September, 2022.”

F.No.PC-II 46016/ 6/2020-Tech.CPC Pt- 2

Kashi Nath Jha, Joint Secretary, Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers, New Delhi.

Note: The principal Order was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), vide number S.O. 3931(E), dated the 13th September, 2021.



India Pavilion at
AFRICA HEALTH ExCon, Cairo, Egypt 5-7 June 2022
Egypt International Exhibition Center (EIEC) : Hall 1

Association have received a communication from Mr Uday Bhaskar, Director- General, Pharmaceuticals Export Promotion Council of India (Pharmexcil), (Set up by Ministry of Commerce & Industry, Government of India), Hyderabad, dated 22nd March 2022 on the above subject as reproduced below:

PXL/HO/Cir-154/2021-22, dated 22nd March 2022

Dear Sir/Madam,

We are pleased to inform that Council as an official International Partner for the event “**Africa Health ExCon**”, (first important trade fair), an initiative of the **Egyptian Authority for Unified Procurement, Medical supply and the Management of Medical Technology (UPA)**, under the auspices of **H.E. President Abdel Fattah El-Sisi** with an objective to

- Refocusing the minds of health & pharma business to Africa’s investment potential.
- Connecting the health care value chain to a fast developing market.
- Driving the healthcare industry to Africa through the right sourcing of products and an equitable distribution.

The Egyptian Authority for Unified Procurement, Medical Supply and the Management of Medical Technology (UPA) is endorsing Africa Health ExCon Exhibition and Conferences to be the continental hub of health innovation and trade in Egypt as well as in Africa.

It seeks to refocus the minds of all those operating in the Health and Pharma business to Africa’s investment potential and thrive the healthcare industry in Africa through the right sourcing of products and equitable distribution to contribute to the continent’s Health Agenda in ensuring equitable access of quality health technology products and services to all African Countries.

This ExCon will take place annually to create a sustainable platform connecting the world healthcare buyers and suppliers under one common roof, giving the chance for All healthcare partners to interact together as well as supporting the flow of trade business intra/extra in the mother continent as it offers numerous opportunities to discover products across several diversified categories, targeting the following sectors:

- | | |
|----------------------------------|--------------------------------------|
| • Medical Supplies & Consumables | • Medical Equipment |
| • Pharmaceuticals | • Laboratory Consumables & Chemicals |
| • Dental Equipment & Supplies | • Dermal Products |
| • Nutrition & Vitamins | • Healthcare Providers |
| • Pharmacies | • Medical Insurance |
| • Feeding Industries | • Packaging |

In this exhibition many national and international companies are exhibiting their products and services. It will provide platform for better network, strengthen business relations and create new businesses opportunities. In addition, there will be an opportunity to attend numerous conferences on trending medical topics in Africa.

The Egyptian Authority for Unified Procurement, Medical Supply and the Management of Medical Technology (UPA) have offered a special discount of 50% to all the Indian companies who are going to participate under India Pavilion in this Mega Trade Fair “Africa Health ExCon”. For more details about the event, please visit www.africahealthexcon.com

The council will be organizing India Pavilion by taking 264 sq. meter space, which is divided into 9 and 12 sq. meter stalls which will be furnished with minimum furniture and the costs of which are as follows:

12 sq. meter stall (4 stalls) : Rs. 2.75 lakhs

9 sq. meter stall (24 stalls) : Rs. 2.00 lakhs

All the Stalls will be furnished with minimum furniture

Allotment of Stalls:

Members may please click on the following links to see the Overall Floor plan of Africa Health ExCon and also India Pavilion.

OVERALL FLOOR PLAN of Africa Health ExCon

With a view to make the allotment procedure easy and transparent, we made the reservation of stalls online. Interested members may please click on the following link reserve as per your choice.

INDIA PAVILION at Africa Health ExCon (the above link will open at 2.30 pm on 04 Apr 2022 only)

Members are required to make the full payment within a week of making a reservation, failing which their reservation automatically gets cancelled. Cancellation is not allowed once the stall is allotted. Amount paid will be forfeited.

Assistance to the participants:

Subject to the release of finances by Ministry of Commerce, Govt. of India and also other rules of MAI scheme (latest guidelines) (via LOGIN) members whose export turnover for the previous year is less than Rs.50 crores and has one year membership with the Council, will be eligible for financial assistance to the extent of Rs.75,000 towards travel expenses.

Location of Pavilion:

Pavilion is located in the middle of Hall 1, surrounded by big exhibitors like Bayer, Pfizer, Novartis, Sanofi, Roche, GSK, Astrazeneca, etc.

Since this is a good opportunity to increase exports in Africa and the Middle-East, we advise the members to take part in the event.

For further information about the event, members may contact us at
webdesk@pharmexcil.com



India Pavilion at KOREA PHARM South Korea, 14-17 June 2022

Association have received a communication from Mr Uday Bhaskar, Director- General, Pharmaceuticals Export Promotion Council of India (Pharmexcil), (Set up by Ministry of Commerce & Industry, Government of India), Hyderabad, dated 16th March 2022 on the above subject as reproduced below:

PXL/HO/Cir-151/2021-22, dated 16th March 2022

We are glad to inform that Council is organizing India Pavilion at Korea Pharm, being held at Korea International Exhibition Center (KINTEX), Goyang, South Korea. This is the 7th time Council is participating in the event. Korea Pharm is an exhibition focused for Pharmaceuticals, Biotech, APIs, Chemicals, Laboratory and Packaging materials. This is the only exhibition supported by MFDS and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA). For more details, please visit their website www.koreapharm.org

India Pavilion: Council offers independent stalls of 9 sq. meters each in India Pavilion, cost of which are as follows:

- 9 sq. meter stand :: Rs. 2.75 lakhs (corner)
- 9 Sqmtr Stand :: Rs. 2.70 lakhs (General)

All the stalls will be furnished with minimum furniture. Large Scale companies are welcome to reserve the stand in the India pavilion and participate in Korea Pharma, but the subsidy is not applicable for them.

Financial Assistance under MSME Ministry (reimbursed post event details provided below with this Circular):

- 100% Booth Cost for MSME Category company only
- 100% Economy Class Airfare for 1 person from 1 company from MSME category only

(Carpet, Wall & Fascia Information Desk, Round Table 1, Chairs: 4, Catalog holder, 220V Electric outlet (under 1KW), Spotlight: 4, waste basket)

Buyer-Seller Meet:

We are happy to inform you that the organizer has assured to arrange minimum 5 to 7 Buyers from Korea and arrange One-to-One Meetings with the exhibitors participating in Indian Pavilion through Pharmexcil.

Allotment of Stalls:

With a view to make the allotment procedure easy and transparent, we made the reservation of stalls online. Interested members may please click on the following link and reserve as per your choice.

Korea Pharm 2022 Overall Floor Plan India Pavilion Floor Plan

ONLINE RESERVATION OF STALLS

(The above link will open at 2.30 p.m. on 17 March 2022 only)

Please note the following terms:

- a) Members can reserve stalls as per their choice, subject to a maximum of 2 stalls only. If any member reserves more than 2 stalls/at different locations, they are required to release one booking, keeping one of their choice. If no mail is received within 15 minutes of booking, Council releases booking one stall, without any notice, to enable others to reserve the stalls.
- b) Payment has to be made within 10 days from the date of reservation, failing which the reservation automatically gets cancelled and it becomes open for other members to reserve.

Cancellation of stalls:

Cancellation is not allowed once the stall is allotted. Reservation of stall gets automatically cancelled, if the payment is not received within the scheduled time


Financial Assistance under MSME Ministry (reimbursed post event details provided below with this Circular):

- 100% Booth Cost for MSME Category company only
- 100% Economy Class Airfare for 1 person from 1 company from MSME category only.

Exhibitors are requested to provide the copy of the Udyam Registration after the stall reservation. The Reimbursement of the above benefits is subjected to the approval and submission of the following documents in original post event to the MSME.

For further details, Members may contact Mr. Murali Krishna, Director at dd.smk@pharmexcil.com Tel: 040-23735462/66.

Note: For more information on Udyam Registration and on the MSME Scheme Guidelines / availing Financial Assistance, please contact Mr. Susanta Mahapatra, MD at md@3smg.in / 9971988322



In Lok Sabha & In Rajya Sabha

In Rajya Sabha

Availability of drugs at reasonable price

Rajya Sabha Starred Question No. *145

Shri Naresh Bansal

Q. Will the Minister of **Chemicals and Fertilizers** be pleased to state:

- (a) the steps being taken by Government to control the prices of drugs and to provide drugs at affordable/ reasonable rates to the poor;
- (b) whether there are benefits of opening Pradhan Mantri Janaushadhi Kendras;
- (c) if so, the details thereof and if not, the reasons therefor; and
- (d) the steps taken to make pharmaceutical companies self-reliant by way of increasing indigenous resources in the country?

Answered on 15th March 2022

A. (a) to (b) A statement is laid on the Table of the House

Minister in the Ministry of Chemicals and Fertilizers (Dr. Mansukh Mandaviya)

Statement referred to in reply to Rajya Sabha Starred Question No. *145# for answer on 15.03.2022 by Shri Naresh Bansal regarding 'Availability of drugs at reasonable price'.

(a): National Pharmaceutical Pricing Authority (NPPA) under the aegis of the Department of Pharmaceuticals fixes the ceiling price of scheduled medicines as per provisions of the Drugs (Prices Control) Order, 2013. In case of non-scheduled medicines, a manufacturer is at liberty to fix the Maximum Retail Price (MRP) launched by it, but is not allowed to increase the MRP of such formulations by more than 10% per annum. NPPA has fixed ceiling prices of 886 scheduled formulations & 4 scheduled medical devices and fixed retail prices of 1,817 new drugs. In addition, it has fixed ceiling price of Orthopedic Knee Implants under Para 19 of DPCO, 2013 in public interest. Moreover, under "Trade Margin Rationalisation" Approach, the NPPA has fixed Trade

Margin of non-scheduled formulations of 42 select Anti-cancer medicines and recently during COVID-19 pandemic, regulated the prices of Oxygen Concentrators, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer and Glucometer.

(b)and(c): With an objective of making quality generic medicines available at affordable prices to all, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has been launched by the Government wherein dedicated outlets are opened to provide quality generic medicines at cheaper rates to the citizens. Under the Scheme, till 28.02.2022, about 8,689 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) have been opened across the country, covering all districts of the country. Jan Aushadhi Medicines are cheaper by 50 -90% of market prices of branded medicines. During the current financial year (till 28.02.2022), total sales of Rs. 814.21 cr. has been achieved, which has led to estimated savings of approximately Rs. 4,800 cr. to the citizens.

(d): In order to attain self-reliance in the pharmaceutical sector, develop global champions and to retain position of the country as 'Pharmacy of the world', the government has launched two Production Linked Incentive (PLI) schemes. PLI scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) was launched with total financial outlay of Rs. 6,940 crore. Under the scheme, 49 applicants have already been approved. The other PLI Scheme for Pharmaceuticals has a total financial outlay of Rs. 15,000 crore. Under this scheme, 55 applicants have been selected. In addition, the department has launched a Scheme for Promotion of Bulk Drug Parks with a total outlay of Rs. 3,000 cr wherein financial assistance is to be provided for creation of Common Infrastructure Facilities in 3 Bulk Drug Parks.

Ayush Medicines for Covid-19

Rajya Sabha Starred Question No.148

Shri P. Wilson:

Q. Will the **Minister of Ayush** be pleased to state:

- (a) the current progress on manufacturing the AYUSH – 64 medicines for COVID-19 developed by the

Central Council of Research in Ayurvedic Sciences; and

- (b) the measures being taken by Government to create awareness amongst people regarding the use of Kabasura Kudineer for mild COVID-19 patients across the country after its successful trials and implementation in Tamil Nadu?

Answered on 15th March 2022

- A. (a) &(b) A Statement is laid on the Table of the House.

Statement Referred to in Reply to Rajya Sabha Starred Question No.148* For 15th March, 2022

(a) The technology of AYUSH-64 was transferred to the interested manufacturers through an agreement from National Research Development Corporation (NRDC) and Central Council for Research in Ayurvedic Sciences (CCRAS). The list of manufacturers to whom the technology of AYUSH-64 is transferred by the concerned agencies as on 7th March, 2022 is placed at **Annexure-I**. The manufacturers after technology transfer obtain license of the product from the concerned State Drug Licensing Authority (SLA). The details of approvals given to such companies by respective SLAs for manufacturing of AYUSH-64 are placed at **Annexure-II**.

(b) Ministry of Ayush on 7th May 2021, through a virtual conference, has launched a nationwide distribution campaign of scientifically validated medicines, i.e., AYUSH 64 and Kabasura Kudineer for the benefit of the vast majority of out of hospital COVID19 patients. The Ministry has also engaged the States/UT, NGOs and volunteers for this nationwide distribution of AYUSH-64 and Kabasura Kudineer.

Institutes under Ministry of Ayush, viz. National Institute of Siddha (NIS) and Central Council for Research in Siddha (CCRS), and the Government of Tamil Nadu have distributed Siddha medicines including Kabasura Kudineer to people in Tamil Nadu and other States like Kerala, Karnataka, Andhra Pradesh, New Delhi for prophylactic

care and for the management of asymptomatic, mild to moderate COVID19 patients. In this connection, NIS has distributed Kabasura Kudineer and Nilavembu Kudineer as prophylaxis medicines to the frontline workers which encompasses police personnel, fire service personnel, civil workers, doctors, nurses, NGOs etc., and as a part of celebration of Azadi Ka Amrit Mahotsav distributed 90,000 Kabasura Kudineer packets and Amukkara Chooranam tablets to the general public. NIS has also distributed Kabasura Kudineer as prophylaxis to around 10,000 police personnel in Delhi. Government of Tamil Nadu has distributed Kabasura Kudineer to nearly 1.80 cr individuals in Chennai, nearly 11 lakhs individuals in home quarantine and nearly 20 lakhs individuals in the containment zones. Recently also, during the outbreak of Omicron variant, CCRS have distributed Kabasura Kudineer to nearly 36,000 individuals.

CCRS has also initiated many programmes for popularizing Kabasura Kudineer among the public through print media in national newspapers, audio jingles, video documentary films and utilizing the Social Media platform (You tube, Twitter and Facebook) to reach the common man.

Further, in order to increase awareness amongst people regarding the use of Kabasura Kudineer for mild COVID-19 patients across the country, Ministry of Ayush has issued guidelines and advisories from time to time. Comprehensive guidelines like 'Guidelines for Siddha Practitioners', 'Guidelines for AYUSH Research' issued by the Interdisciplinary AYUSH Research & Development Task Force, advisory regarding 'Ayush Guidelines for COVID-19 patients under home isolation', advisory on Ayush interventions on prophylaxis and management of Covid-19' which also contained detailed instructions regarding usage of Siddha medicines for Covid-19 patients. These efforts have given a niche in reaching out to the common man of the country.

**The Minister of Ayurveda, Yoga & Naturopathy,
Unani, Siddha And Homoeopathy(Ayush)
(Shri Sarbananda Sonowal)**

Annexure-I

LIST OF MANUFACTURING UNITS TO WHICH AYUSH-64 TECHNOLOGY HAS BEEN TRANSFERRED

Sr. No.	Name of the Company	State/UT
1.	M/s Indian Medicines Pharmaceuticals Co. Ltd. (IMPCL), Mohan, Ramnagar, Distt. Almora	Uttarakhand
2.	M/s Multani Pharmaceuticals Ltd., New Delhi.	NCT of Delhi

3.	M/s Upkaran Pharmaceuticals , Shop No. 25, Board Office Square, Zone-II, Maharana Pratap Nagar, Bhopal, Madhya Pradesh 462011	Madhya Pradesh
4.	M/s Dabur India Pvt. Ltd. , Sahibabad, Ghaziabad	Uttar Pradesh
5.	M/s Jamna Herbal Research Limited , 15, Zone-II, Maharana Pratap Nagar, Bhopal	Madhya Pradesh
6.	Uttarakhand State Medicine & Pharmaceuticals Ltd. , Haldwani, U.K.	Uttarakhand
7.	M/s Sarvotham Care Limited , 197, Nicholson Road, Tadbund, Secunderabad, Telangana- 500009	Telangana
8.	M/s Dindoyal Industries Ltd. , 5-6, Industrial Estate, Tansen Road, Birla Nagar, Gwalior- 474004, M.P.	Madhya Pradesh
9.	M/s Dhootpapeshwar Ltd. , Veer Savarkar Chowk, Panvel, Raigad-410206, Maharashtra	Maharashtra
10.	M/s Dhatri Ayurveda Pvt. Ltd. , 33/1882B, Adappilly Road, Ernakulum, Kerala	Kerala
11.	M/s Tirupati Medicare Ltd. , Paonta Sahib, Distt. Sirmour, H.P.	Himachal Pradesh
12.	M/s Sriveda Sattva Private Ltd. , Third Floor, No. 54/46, 39 th A Cross, 11 th Main Road, 4 th T Block, Jayanagar, Bangalore, Karnataka-560041	Karnataka
13.	M/s Revinto Life Science Pvt. Ltd. , Plot No. 21, KIDAB Industrial Area, Shirwada, Karwar, Uttara Kannada District, Karnataka- 581306	Karnataka
14.	M/s Karnani Pharmaceuticals Pvt Ltd. 19/23,Vithoba Lane, Vithalwadi, Mumbai, Maharashtra- 400002	Maharashtra
15.	OM Pharmaceuticals Ltd. , 202, Vishwa Nanak Apartments, GurunanakWadi, Chakala, Andheri (East), Mumbai, Maharashtra- 400099	Maharashtra
16.	Karnataka Antibiotics & Pharmaceuticals Ltd. , Dr. Rajakumar Road, First Block, Rajajinagar, Bangalore-560010	Karnataka
17.	M/s Desh Rakshak Aushdhalya Ltd. , Kankhal, Haridwar-249408	Uttarakhand
18.	M/s S.D.P. Remedies and Research Centre , Business Office at Udayagiri, Korungu, Kemminje, Village Puttur, DK, Karnataka-574202	Karnataka
19.	M/s Meghdoot Gramodyog Sewa Sansthan , A1/18, Sector- H, Puraniya Chauraha, Aliganj, Lucknow , U.P.	Uttar Pradesh
20.	M/s Amulya Labs Private Ltd. , Plot No 74, Industrial Estate HSIIDC, Alipur, Barwala, Panchkula, Haryana- 134118	Haryana
21.	M/s Uma Ayurvedics Private Ltd. , Madhav Puri, Nadrai Gate, Kasganj (Etah), 207123, U.P.	Uttar Pradesh
22.	M/s Basic Ayurveda 46, Anand Industrial Estate, Mohan Nagar, Ghaziabad- 201007, U.P.	Uttar Pradesh
23.	M/s Alna Biotech Pvt. Ltd. SCF 1013, Ground Floor Motor Market, Manimajra, Chandigarh-160101	Haryana jurisdiction
24.	M/s Pharmaveda (India) Private Ltd. B-4 Kamdar Shopping Centre, Opp Railway Station Vile Parle (East), Mumbai, Maharashtra- 400057	Maharashtra
25.	M/s Pharmaceutical Corporation (IM) Kerala Ltd. Kuttanellur P.O., Trissur, Kerala- 680014	Kerala

26.	M/s Amar Pharmaceuticals and Labs (India) Pvt. Ltd. 17/110 Nawab Compound, Ram Narain Bazar, Kanpur, Uttar Pradesh-208001	Uttar Pradesh
27.	M/s Shree Dhanwantri Herbals , Village Kishanpura, Tehsil Nalagarh, District Solan, Himachal Pradesh-174101	Himachal Pradesh
28.	M/s Maheshwari Pharmaceuticals (India) Ltd. , Plot No. 7, Sector 6B IIE SIDCUL, Haridwar, Uttarakhand-249403	Uttarakhand
29.	M/s HLL Lifecare Limited HLL Bhavan, Mahilamandiram Road, Poojappura, Thiruvananthapuram, Kerala- 69	Kerala
30.	M/s Bipha Drug Laboratories Private Ltd. XIII/804, Pallipurathukavu Junction, Kottayam, Kerala- 686039	Kerala
31.	M/s Himalaya Research Laboratory , EPIP, Bari Brahmna, Jammu-181133	J & K
32.	M/s Mangalam Biotech Research 39/23, 2nd Floor, Lane No. 15, Sameyapur Industrial Area, Delhi-110042	Delhi
33.	M/s North India Life Sciences Private Limited Plot No-430, Sec-3, HSIIDC Karnal, Haryana- 132001	Haryana
34.	M/s Nirav Healthcare , Plot No. 25, GIDC Phase-I, Industrial Estate, Rajpipla, Narmada, Gujarat-393145	Gujarat
35.	M/s Minor Forest Produce Processing & Research Centre , Van Parisar, Barkheda, Pathani, Bhopal-462021	Madhya Pradesh
36.	M/s Multi State Cooperative Pharmaceuticals & Research , Lane No. 1, MangalParao, Haldwani, Nainital -263139, Uttarakhand	Uttarakhand
37.	Co-operative Drug Factory Udyog Nagar, Ganiadeoli, Ranikhet, Almora, Uttarakhand-263645	Uttarakhand
38.	M/s Baijnath Pharmaceuticals Pvt Ltd. , P.O. Paprola, Tehsil Baijnath, Distt. Kangra, Himachal Pradesh-176115	Himachal Pradesh
39.	M/ s Rajasthan Herbal International Pvt Ltd. , F- 143, IInd Phase, Riico Industrial Area, Jhunjhunu, Rajasthan- 333001	Rajasthan
40.	M/ s Nagarjun Pharmaceuticals Pvt Ltd. Sherisa, Kalol-Khatraj Road, Kalol, Gandhinagar, Ahmedabad, Gujarat- 382721	Gujarat
41.	M/s Hamdard Laboratories (India)- Medicine Division , Hamdard Building, 2A/3 Asaf Ali Road, New Delhi-110002	New Delhi
42.	M/s Royal Bee Natural Products Pvt. Ltd. , S- 16 Loni Road, Site-2, Mohan Nagar, Ghaziabad- 206002 U.P.	Ghaziabad
43.	Aayukart Private Ltd. , H1-2213, RIICO Industrial Area, Ramchandrapura, Sitapura Extension, Jaipur, Rajasthan- 302022	Jaipur
44.	M/s Goa Antibiotics & Pharmaceuticals Ltd. , Tuem Industrial Area, Tuem, Pernem, Goa- 403512	Goa
45.	M/s Zeon Life Sciences Ltd. , Village Kunja, Rampur Road, Paonta Sahib, Himachal Pradesh- 173025	Himachal Pradesh
46.	M/s Haritha Pharmaceuticals , Building No. 332, Vadakkumuri, Varandarappilly, Thrissur, Kerala- 680303	Kerala

LIST OF LICENSED MANUFACTURERS OF AYUSH-64 ALONGWITH THEIR BRAND/MARKET NAMES OF THE DRUG

S.No.	State/UT	Company Name	Brand Name
1.	Karnataka	i. M/s OM Pharmaceuticals Ltd., 12 th Mile stone old Madras Road, Virgonagar post, bengluru-49	AYUSH-64
		ii. M/s Revinto Life Science Pvt. Ltd, Plot No.21, KIDAB Industrial Area, Shirwad, Karwar-581301	Recomax (AYUSH-64)
		iii. M/s SDP Remedies & Research Centre, 2-120(2), Udayagiri, Mundoor, Puttur Taluk Dakshina, Kannada-574202	AYUSH-64
2.	Punjab	i. M/s Dhanwantri Herbals, Amritsar	AYUSH-64
		ii. M/s IMPCL C/o Shri Dhanwantri Herbal, Amritsar (Loan License)	AYUSH-64
		iii. M/s Prabhar Ayurvedic Pharmacy, Amritsar	AYUSH-64
		iv. M/s Shri Krishna Ayurvedic Herbal, Amritsar	AYUSH-64
		v. M/s Curoveda Herbal, Amritsar	AYUSH-64
		vi. M/s Caulis Healthcare, Ludhiana	AYUSH-64
		vii. M/s Arogya Pharmacy, Mansa	AYUSH-64
3.	Kerala	i. M/s Dhathri Ayurveda Pvt. Ltd. Door No. MP 46/3578, Adappilly road, Vennala, P.O. Ernakulam District-682028, Kerala	AYUSH-64
		ii. M/s The Pharmaceutical Corporation (IM) Kerala Ltd (Oushadhi), Door No. IX/590 to 599, Kuttanellur, Thrissur District.	AYUSH-64
		iii. M/s. Bipha Drug Laboratories Pvt. Ltd., Door No. B1, B2, B3, B4, Industrial Estate, Ettumanoor, Kottayam District, Kerala.	AYUSH-64
4.	Himachal Pradesh	i. M/s Tirupati Medicare Ltd., Nahan Road, Poanta Sahib, Distt. Sirmour, H.P.	AYUSH-64 Tablet
		ii. M/s Sarvotham Care, village Jharmajri, Barotiwala-Baddi Rload, Tehsil-Baddi, Distt. Solan, H.P.	AYUSH-64 Tablet
		iii. M/s Baijnath Pharmaceuticals Pvt. Ltd. PO Paprola, Tehsil-Baijnath, Distt. Kangara, H.P.	AYUSH-64 Tablet
5.	Uttarakhand	i. M/s Indian Medicine Pharmaceuticals Corporation Ltd. (IMPCL), Unit-II, Khasra No. 673, Imlikhera, Roorke, Haridwar	AYUSH-64 Tablet
		ii. M/s Sriveda Sattva Pvt. Ltd. Plot no. 13 & 14, Sigaddi Growth Centre, Kotdwar, Pori Garhwal	AYUSH-64 Tablet
		iii. M/s Indian Medicine Pharmaceuticals Corporation Ltd. (IMPCL), Mohan Almora	AYUSH-64 Tablet
		iv. M/s Multani Pharmaceuticals Ltd., Khasra No. 37, Village-Makkanpur, Bhagwanpur, Roorkee, Haridwar	AYUSH-64 Tablet

		v. M/s Deshrakshak Aushdhalaya Ltd., Bhagwant Kuti, Kankhal, Haridwar	AYUSH-64 Tablet
		vi. M/s HLL Lifecare Ltd. Khata No. 98. Khasra No. 37, Village-Makkanpur, Bhagwanpur, Roorkee, Haridwar	AYUSH-64 Tablet
		vii. M/s Maheswari Pharmaceuticals (India) Ltd., Plot no.7, Sector- 6B, IIE, Haridwar	AYUSH-64 Tablet
		viii. M/s Karnani Pharmaceuticals Pvt. Ltd, 38, Pharmacy, Selakui, Dehradun	AYUSH-64 Tablet
6.	Tamil Nadu	M/s Ancient Pharma, Madurai	Plasmodin (AYUSH-64)
7.	Rajasthan	i. Karnani Pharmaceuticals Pvt. Ltd., F-67 Industrial area Bhiwadi, Rajasthan-301019	CORO-STOP (AYUSH-64) TABLET

Integration of Traditional Medicine with Modern System of Medicine

Rajya Sabha Unstarred Question No.1445

Smt. Ambika Soni:

Q. Will the Minister of **AYUSH** be pleased to state:

- whether Government has formulated any plan for integrating traditional medicine with the modern system of medicine;
- if so, the details thereof; and
- the steps taken by Government to adopt a comprehensive and specific course of action to re-discover the glorious past of AYUSH systems that reigned and ruled the world health care system?

Answered on 15th March 2022

A. (a)&(b) The Government of India has taken the following steps for integrating traditional medicine with the modern system of medicine:

- Government of India has adopted a strategy of Co-location of AYUSH facilities at Primary Health Centres (PHCs), Community Health Centres (CHCs) and District Hospitals (DHs), thus enabling the choice to the patients for different systems of medicines under a single window. The engagement of AYUSH doctors/ paramedics and their training is supported by the Ministry of Health & Family Welfare, while the support for AYUSH infrastructure, equipment/ furniture and medicines are provided by the Ministry of Ayush under shared responsibilities. The number of AYUSH facilities co-located at Primary Health Centres (PHCs), Community Health Centres (CHCs) and District Hospitals (DHs), State/

UTwise under National Health Mission (NHM) is furnished at Annexure.

- There are provisions in the National Commission of Indian System of Medicine Act, 2020 and National Commission of Homoeopathy Act, 2020 to conduct joint sitting of National Commission of Indian System of Medicine (NCISM) and National Commission for Homoeopathy (NCH) with the National Medical Commission at least once a year to enhance the interface between modern and traditional systems.
- The NITI Aayog, Government of India has constituted four working groups to establish an Integrated Health System under Public Health and Administration and further chalk out the integration in the four main core areas of education, medicine, clinical research and public health & administration.
- AYUSH is being integrated with various new and upcoming All India Institute of Medical Sciences (AIIMS) being established under the Ministry of Health & Family Welfare. A Joint Coordination Committee (JCC) comprising members from the Ministry of Health & Family Welfare and the Ministry of Ayush has been constituted to work out modalities for effective and expeditious integration of AYUSH in new and upcoming AIIMS.
- Under Centre of Excellence component of AYURSWASTHYA Yojana, Ministry of Ayush has provided financial assistance to Centre for Integrative Medicine and Research (CIMR), All India Institute of Medical Sciences (AIIMS), New Delhi and Institute of Liver and Biliary Sciences (ILBS), New Delhi for integration with AYUSH.

- (vi) A Memorandum of Understanding has been signed between All India Institutes of Ayurveda (AIIA), New Delhi and AIIMS, New Delhi to execute various activities at the proposed Centre of Ayurveda and Integrative Oncology at National Cancer Institute (NCI) Jhajjar of All India Institute of Medical Sciences (AIIMS).
- (vii) In order to have Inter-disciplinary research, the Ministry of Ayush has formed an Interdisciplinary Ayush R&D Task Force having representation from the Indian Council of Medical Research (ICMR), Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR), All India Institute of Medical Sciences (AIIMS) and AYUSH Institutions. Based on recommendations of the Task force, under various research organizations and National Institutes under the Ministry of Ayush, 142 research studies in the country are being conducted on AYUSH interventions on Covid-19.

(c) Government of India is implementing a Centrally Sponsored Scheme of National AYUSH Mission (NAM) in the country for promotion and development of AYUSH system through States/UTs. The Research Councils under the Ministry of Ayush are functioning with the objective of the development of safe & effective formulations/therapies for the management of diseases of national importance, revalidation of classical formulations for generating evidence on safety and efficacy, capacity building in the core research area and research-oriented public health activities. Further, Ministry of Ayush is also propagating the AYUSH system of medicine through National Institutes by providing AYUSH education, research and patient care.

The proactive efforts made by India in positioning the AYUSH as the soft power of India and at the same time generating evidence about the health benefits as well as safety of these systems has given a significant boost to the demand of Ayurveda, Yoga and other Indian traditional systems of medicine across the world. The Ministry developed a Central Sector Scheme for Promotion of International Cooperation with the mandate to promote and strengthen awareness about AYUSH Systems of Medicine; to facilitate international promotion, development and recognition of AYUSH Systems in foreign

countries; to establish AYUSH centres in foreign countries; to support international exchange of experts and information; to give a boost to AYUSH products in International market and to establish AYUSH Academic Chairs in foreign countries.

**The Minister of Ayush
(Shri Sarbananda Sonowal)**

Annexure

The number of AYUSH facilities co-located at Primary Health Centres (PHCs), Community Health Centres (CHCs) and District Hospitals (DHs), State/UT-wise under National Health Mission (NHM)

Sr. No.	Name of the State/UT	DH	CHC	PHC
1	Bihar	36	0	0
2	Chhattisgarh	18	98	454
3	Himachal Pradesh	1	32	101
4	Jammu & Kashmir	20	13	375
5	Jharkhand	24	48	97
6	Madhya Pradesh	36	87	305
7	Odisha	3	314	1162
8	Rajasthan	1	169	728
9	Uttar Pradesh	102	666	627
10	Uttarakhand	13	53	44
11	Arunachal Pradesh	0	0	0
12	Assam	0	0	0
13	Manipur	7	17	78
14	Meghalaya	11	24	55
15	Mizoram	9	9	9
16	Nagaland	9	20	9
17	Sikkim	4	1	4
18	Tripura	3	21	84
19	Andhra Pradesh	9	105	273
20	Goa	2	6	24

21	Gujarat	0	0	886
22	Haryana	21	97	109
23	Karnataka	14	70	395
24	Kerala	0	0	0
25	Maharashtra	23	238	20
26	Punjab	20	62	134
27	Tamil Nadu	20	385	537
28	Telangana	8	46	479
29	West Bengal	16	213	222
30	A&N Island	3	4	20
31	Chandigarh	1	2	0
32	D&N Haveli/D&D	2	4	11
33	Delhi	43	0	135
34	Ladakh	2	0	32
35	Lakshadweep	2	3	4
36	Puducherry	4	4	39
All India		487	2811	7452

Source: NHM-MIS report, September, 2021

Promotion of Traditional System of Medicine

Rajya Sabha Unstarred Question No. 1448

Smt. Jharna Das Baidya:

Q. Will the Minister of **AYUSH** be pleased to state:

- whether Government is making efforts to set up regulatory mechanism, quality education and research in order to promote traditional system of medicine;
- if so, the details thereof; and
- the steps being taken in this regard particularly for the North Eastern States?

Answered on 15th March 2022

- A.** (a) Yes, Madam. The Ministry of Ayush promotes and propagates the Indian System of Medicine and Homoeopathy across the country through its national institutes, apex central research councils and

statutory regulatory bodies to regulate the education, practice and research relating to Ayurveda, Yoga, Naturopathy, Siddha, Sowa-Rigpa, Unani and Homoeopathy.

(b) Central Government has established separate National Institutes and separate Central Research Councils for each system of Medicine under the Ministry of Ayush. The list of Institution of national importance/All India Institute of Ayurveda/National Institutes, Research Councils functioning under the Ministry of Ayush are at Annexure-1. In order to regulate the practice and impart quality education, Ministry of Ayush has set up the National Commission for Indian System Medicine and the National Commission for Homoeopathy under the provisions of the National Commission for Indian System of Medicine Act, 2020 and the National Commission for Homoeopathy Act, 2020, respectively. Further, for standardisation of Ayurveda, Siddha, Sowa-Rigpa, Unani and Homoeopathy drugs, Central Government has established Pharmacopoeia Commission for Indian Medicine & Homoeopathy, which also acts as a Central Apex Laboratory.

(c) In order to promote the Indian System of Medicine and Homoeopathy in the North Eastern States, Ministry of Ayush has established National Institutes and units of Central Research Councils for Ayurveda, Unani and Homoeopathy System of Medicine. The list of National Institutes, Research Councils functioning under the Ministry of Ayush in the North Eastern States are at Annexure-II.

Further, the Government of India is implementing Centrally Sponsored Scheme of National AYUSH Mission(NAM) in the country for promotion and development of AYUSH systems through States/UTs including North Eastern States. Under NAM, there is provision for granting financial assistance for the establishment of new AYUSH Colleges in the States where the availability of AYUSH teaching institutions is inadequate in Government Sector and Infrastructural development of AYUSH Under-Graduate/Post Graduate Institutions. State/UT Governments, including North Eastern States may avail eligible financial assistance by projecting the same through State Annual Action Plan (SAAP) as per NAM guidelines.

Minister of Ayush (Shri Sarbananda Sonowal)

Annexure-1**A. List of Institution of National Importance/All India Institute of Ayurveda/National Institutes of the different streams: -**

S. No.	INI/AIIA/National Institutes	State/ UT
1	Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat.(INI)	Gujarat
2	All India Institute of Ayurveda, SaritaVihar, New Delhi.(AIIA)	New Delhi
3	National Institute of Ayurveda, Jaipur, Rajasthan.	Rajasthan
4	National Institute of Homoeopathy, Kolkata, West Bengal.	West Bengal
5	National Institute of Naturopathy, Pune , Maharashtra.	Maharashtra
6	Morarji Desai National Institute of Yoga, New Delhi.	New Delhi
7	National Institute of Unani Medicine, Bengaluru, Karnataka.	Karnataka
8	National Research Institute of Unani Medicine for Skin Disorders, Hyderabad, Telangana.	Telangana
9	National Institute of Siddha, Chennai, Tamil Nadu.	Tamil Nadu
10	North Eastern Institute of Ayurveda & Homoeopathy, Shillong, Meghalaya.	Meghalaya
11	North Eastern Institute of Ayurveda & Folk Medicine Research, Pasighat, Arunachal Pradesh.	Arunachal Pradesh
12	National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala.	Kerala
13	National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur, Kerala.	Kerala
14	Rashtriya Ayurveda Vidyapeeth, Punjabi Bagh (West), New Delhi.	New Delhi
15	National Institute for Sowa Rigpa, Leh, Ladakh.	UT Ladakh

B. List of Research Councils of the different streams: -

S.No.	Research Councils	State/ UT
1	Central Council for Research in Ayurveda Science,Janakpuri, New Delhi.	New Delhi
2	Central Council for Research in Homoeopathy,Janakpuri, New Delhi.	New Delhi
3	Central Council for Research in Unani Medicine, Janakpuri, New Delhi.	New Delhi
4	Central Council for Research in Siddha, Arumbakkam, Chennai, Tamil Nadu.	Tamil Nadu
5	Central Council for Research in Yoga & Naturopathy,Janakpuri, New Delhi.	New Delhi

Annexure-II**A. List of National Institutes of the different streams in the North East Region: -**

Sr. No.	National Institutes	State/ UT
1	North Eastern Institute of Ayurveda & Homoeopathy, Shillong, Meghalaya.	Meghalaya
2	North Eastern Institute of Ayurveda & Folk Medicine Research, Pasighat, Arunachal Pradesh.	Arunachal Pradesh

B. List of the Research Institute/Units/ Centre under the Central Research Councils of the different streams in the North East Region: -

Sr. No.	Unit of Research Councils	Stream	State
1.	Central Ayurveda Research Institute, (CARI), Guwahati, Assam.	Ayurveda	Assam
2.	Regional Ayurveda Research Institute, (RARI) Itanagar, Arunachal Pradesh.	Ayurveda	Arunachal Pradesh
3.	Regional Ayurveda Research Institute, (RARI) Gangtok, Sikkim.	Ayurveda	Sikkim
4.	Regional Ayurveda Research Centre, (RARC), Agartala Tripura.	Ayurveda	Tripura
5.	Regional Ayurveda Research Centre, (RARC) Dimapur, Nagaland.	Ayurveda	Nagaland
6.	The Councils Regional Research Centre (Unani), Silchar, Assam.	Unani	Assam
7.	Regional Research Institute (Homoeopathy), Guwahati, Assam.	Homoeopathy	Assam
8.	Regional Research Institute (Homoeopathy), Imphal, Manipur.	Homoeopathy	Manipur
9.	Clinical Research Unit (Homoeopathy), Dawrpui , Aizwal, Mizoram.	Homoeopathy	Mizoram
10.	Clinical Research Unit (Homoeopathy), Dimapur, Nagaland.	Homoeopathy	Nagaland
11.	Clinical Research Unit (Homoeopathy), Gangtok, Sikkim.	Homoeopathy	Sikkim
12.	Regional Research Institute (Homoeopathy), Agartala, Tripura.	Homoeopathy	Tripura

In Lok Sabha

Bilateral Trade Pact Between India and UAE

Lok Sabha Unstarred Question No. 2442

Shri Kotha Prabhakar Reddy:

Q. Will the Minister of **COMMERCE & INDUSTRY** be pleased to state:

- whether India and the United Arab Emirates (UAE) signed a bilateral comprehensive trade pact for investment from the Gulf country into Jammu and Kashmir which would open new routes for regional trade and connectivity and advance collective interests of India; and
- whether this agreement is likely to herald a new age in financial relations; and
- if so, the details thereof and the progress made as on date in this regard?

Answered on 16th March 2022

A. (a) to (c): On 7th October, 2021, Government of Dubai signed a Memorandum of Understanding (MoU) with the Government of Jammu and Kashmir for real estate development, industrial parks, IT towers,

multipurpose towers, logistics, medical college, super specialty hospital and more. Subsequently, various UAE based companies, have entered into agreements/MoUs with the administration of Jammu and Kashmir for investments in various sectors, including food processing, logistics, retail, real estate, ports, and hospitality.

Moreover, India and the United Arab Emirates (UAE) signed the Comprehensive Economic Partnership Agreement (CEPA) on 18th February, 2022, on the side-lines of the India-UAE Virtual Summit. The India-UAE CEPA is a comprehensive agreement, which will cover, inter alia, Trade in Goods, Rules of Origin, Trade in Services, Technical Barriers to Trade (TBT), Sanitary and Phytosanitary (SPS) measures, Dispute Settlement, Movement of Natural Persons, Telecom, Customs Procedures, Pharmaceutical products, Government Procurement, Intellectual Property, Investment and Trade, Digital Trade and Cooperation in other Areas. The India-UAE CEPA provides for an institutional mechanism to encourage and improve bilateral trade and investments between the two countries. The India-UAE CEPA will also create new employment opportunities across multiple labour-intensive sectors like gems and jewellery, textiles, leather, footwear, furniture, agriculture

and food products, plastics, engineering goods, pharmaceuticals, medical devices, sports goods etc., raise living standards, and improve the general welfare of the people of the two countries.

The Minister of State in the Ministry of Commerce and Industry (Smt. Anupriya Patel)

Investment in Industrial Sector

Lok Sabha Unstarred Question No. 2369

Dr. Sanjeev Kumar Singari:

Q. Will the Minister of **COMMERCE AND INDUSTRY** be pleased to state:

- (a) whether any steps are being taken by the Government to improve private interest for investment in the industrial sector and increase industrial credit growth, if so, the details thereof;
- (b) whether the Government is aware that most industrial projects of Rs. 1,000 crore to Rs. 5,000 crore budget have taken between 7 to 11 years for completion;
- (c) if so, whether the Government is taking any steps to cut down the time for completion of future industrial projects and make them more cost and time efficient;
- (d) if so, the details thereof and if not, the reasons therefor;
- (e) whether the Government has any data on the number of projects which were stalled, the number of projects which were initiated but delayed and the number of projects which were abandoned; and
- (f) if so, details thereof and if not, the reasons therefor?

Answered on 16th March 2022

- A.** (a): Recently Government has taken various steps to boost domestic investments in India. These include, Promoting FDI (Foreign Direct Investment) and improve Ease of Doing Business, Make in India initiative, National Infrastructure Pipeline, Reduction in Corporate Tax, easing liquidity problems of NBFCs (Non Banking Financial Companies) and Banks, trade policy measures, constitution of Investment and Project Development Cells, One District One Product (ODOP), and PLI (Production Linked Incentive) Scheme for 14 key sectors etc. Government of India is also taken up various Industrial Corridor Projects

as part of National Industrial Corridor Programme which is aimed at development of greenfield industrial nodes/regions which can compete with the best manufacturing and investment destinations in the world.

(b) to (f): The time taken for completion of a project depends on factors like type of project, number of stakeholders, statutory clearances, various other issues related to project etc.

In order to minimize delays and for timely completion of projects, the Government has institutionalized a monitoring mechanism called Project Monitoring Group (PMG) for various infrastructure and industrial projects above Rs. 500 Crore. The PMG reviews such projects and resolve issues related various central ministries as well as State Government. Private Companies can also upload their issues on this portal and get their issues resolved. As per available information, out of total 1805 Projects on the PMG Portal, 442 Projects under implementation have reported issues. Further, 421 projects have been commissioned after resolution of issues.

Department for Promotion of Industry and Internal Trade (DPIIT) also has 32 green field industrial nodes across 11 Industrial Corridors in the Country. National Industrial Corridor Development Corporation (NICDC) as well as DPIIT monitors these project on regular basis.

The Government has also developed PM GatiShakti National Master Plan which is supported by a digital platform to enable synchronized planning for providing multi modal infrastructure connectivity to various economic zones, including industrial parks and clusters.

The Minister of State in the Ministry Of Commerce & Industry (Shri Som Parkash)

Agreement With UAE

Lok Sabha Unstarred Question No. 2432

Shri Girish Bhalchandra Bapat:

Shri Rahul Ramesh Shewale:

Shri Chandra Sekhar Sahu:

Dr. Pritam Gopinathrao Munde:

Q. Will the Minister of **COMMERCE & INDUSTRY** be pleased to state:

- (a) whether India and UAE agreed for Comprehensive Economic Partnership Agreement recently;
- (b) if so, the details thereof and the extent to which it is likely to be beneficial for MSMEs, Startups, farmers, traders and all sections of business in both the countries;
- (c) the details of offers UAE have agreed to extend to India under this agreement;
- (d) whether bilateral goods trade between the two countries will boost on implementation of CEPA;
- (e) if so, the details thereof along with the targets of various sectors fixed for such trade; and
- (f) the details of the employment opportunities likely to be increased in the country due to this agreement?

Answered on 16th March 2022

A. (a) to (b): Yes. India and the United Arab Emirates (UAE) signed the Comprehensive Economic Partnership Agreement (CEPA) on the side-lines of the India-UAE Virtual Summit held on 18th February, 2022. The India-UAE CEPA is a comprehensive and balanced partnership agreement which will give enhanced market access for India in both goods and services. The India-UAE CEPA will be extremely beneficial for MSMEs, start-ups, farmers, traders, and all sections of businesses by opening new markets, enhancing exports and boosting our economy. Further, the India-UAE CEPA will not only increase exports of goods from India to the UAE but also to the Middle East and Africa.

(c): UAE has offered immediate market access at zero duty from day one of the entry into force of the Agreement to products accounting for around 90% of India's exports to the UAE in value terms. Overall, India will benefit from preferential market access provided by the UAE on over 97 % of its tariff lines which account for around 99% of Indian exports to the UAE in value terms. As regards trade in services, the UAE has offered market access to India in around 111 sub-sectors from the 11 broad service sectors.

(d) to (f): Yes. Bilateral trade in goods is projected to increase from the current USD 60 billion to USD 100 billion annually within five years of implementation

of the India-UAE CEPA. Further, the India-UAE CEPA is expected to create a large number of new employment opportunities especially across multiple labour-intensive sectors such as Gems and Jewellery, Textiles, leather, footwear, sports goods, plastics, furniture, agricultural and wood products, engineering products, medical devices, and Automobiles.

The Minister of State in the Ministry of Commerce And Industry (Smt. Anupriya Patel)

FTA WITH UK

Lok Sabha Unstarred Question No. 2481 (H)

Shri Rattan Lal Kataria:

Q. Will the Minister of **COMMERCE & INDUSTRY** be pleased to state:

- (a) whether the Government has signed any Free Trade Agreement (FTA) with Britain on 15 January, 2022;
- (b) if so, the details thereof;
- (c) the details of the investments likely to be made in both the countries alongwith the number of jobs likely to be created as a result of the said agreement;
- (d) whether the Government is likely to sign any FTA with some other countries by the end of the year 2022; and
- (e) if so, the details thereof?

Answered on 16th March 2022

A. (a) to (c): No, Sir. India-UK Free Trade Agreement (FTA) negotiations have been launched on 13th January 2022. Both the sides aim to conclude the negotiations for a balanced and mutually beneficial trade agreement keeping in mind the ambitions and sensitivities of both the sides, with an intent to increase the bilateral flows of trade and investment.

(d) & (e): Government is negotiating FTAs with a few other countries. However, the deadline for completion of an FTA negotiation cannot be predicted as an agreement is reached only when the negotiating parties are satisfied with the outcome.

The Minister of State in the Ministry of Commerce And Industry (Smt. Anupriya Patel)

Free trade agreements: Panel recommends FTA review regime for mid-way corrections

The panel also suggested that the foreign trade policy (FTP) be firmed up within the stipulated time-frame. The FTP for 2015-20 was extended by two years through March 2022 following the Covid outbreak to ensure policy continuity.

India should pursue FTAs or preferential trade pacts with the countries that seek to invest here under the strategy, the report said.

As India gears up to forge a raft of balanced free trade agreements (FTAs), a Parliamentary panel has recommended that New Delhi include a review mechanism in such pacts to ensure “mid-way course correction for any asymmetries” in trade with the partners. A report by the Parliamentary Standing Committee on Commerce, submitted on Tuesday, also called for expeditious conclusion of FTAs to reap benefits.

An FE analysis suggests, in five out of six of India’s prominent FTAs, which came into force between 2006 and 2011, have exacerbated New Delhi’s trade balance. This significantly contributed to the country’s unease over getting into fresh pacts for about a decade before the government decided to sign a deal with the UAE last month. Another interim trade deal with Australia will be announced anytime now.

The panel said that India should leverage the ‘China Plus One Strategy’ to emerge as an alternative investment destination for multinational companies. The growing preference of firms located in Europe and the US to shift from China to other manufacturing bases offers a golden opportunity for India that needs to be taken advantage of, it said. India should pursue FTAs or preferential trade pacts with the countries that seek to invest here under the strategy, the report said.

Importantly, the House committee has said that the imposition of minimum alternate tax and the introduction of sunset clause for income tax relief would impact the competitive advantages of special economic zone units. “The committee recommends that the government should ensure the continuation of fiscal benefits and extension of a sunset clause to retain the competence of SEZ units,” the report said. It also added that SEZs can have the benefits

of Remissions of Duties and Taxes on Exported Products (RoDTEP) scheme, which is now applicable to domestic exporters.

It has also expressed concerns over the reduction in export incentives and suggested some of the sectors that have been kept out of the purview of the government’s flagship tax remission schemes be included. The sectors include pharmaceuticals, organic and inorganic chemicals and iron and steel.

The panel also suggested that the foreign trade policy (FTP) be firmed up within the stipulated time-frame. The FTP for 2015-20 was extended by two years through March 2022 following the Covid outbreak to ensure policy continuity.

On exports, the panel said: “The committee recommends that the department (of commerce) should identify the infirmities and opt for a more focused approach in increasing market access of the sectors that exhibit a downtrend in exports.”

Source: *Financial Express*, 23.03.2022



India, UAE free trade agreement may come into force from May 1, says Goyal



Dubai: The free trade agreement between India and the UAE is likely to come into effect from May 1 this year, under which domestic exporters of as many as 6,090 goods from sectors like textiles, agriculture, dry fruits, gem and jewellery would get duty-free access to the UAE market,

Commerce and Industry Minister Piyush Goyal said on Sunday.

The Comprehensive Economic Partnership Agreement (CEPA) was signed by India and the United Arab Emirates (UAE) in February which aims to boost bilateral trade to \$100 billion in the next five years from current \$60 billion.

The Minister said that the detailed text of the pact has been released in public domain and now we are trying to complete all our paperwork, all the customs notifications expeditiously. We hope it can be operationalised by May 1, 2022.

Overall, the UAE is offering duty elimination on over 97 per cent of its products which account for 99 per cent of Indian exports here in value terms.

Immediate duty-free access covers all labour-intensive sectors such as gems and jewellery, textiles and apparel, agricultural and fish products, leather, footwear, and sport goods, Pharmaceuticals and Medical devices, and many engineering products.

“Currently, we are exporting about \$26 billion worth of goods to the UAE, almost 90 per cent of them will get total tariff (or customs duty) elimination on Day 1 itself. Going forward in the next 5-7 or ten years, the rest of the 9.5 per cent (about 1,270 goods) will also get zero duty,” Goyal said at the Dubai Expo here. Explaining the importance of the pact, he said the UAE also opened doors for the rest of the Middle East, some parts of Africa and Europe. This opens up huge opportunities for Indian businesses, he said adding the pact also opens doors to several service sectors which will expand job opportunities for Indian young boys and girls.

Key areas of India's interest are computer related services, audio visual, education, health, tourism, travel, professionals services like nursing, engineering, and accountancy.

We are also working for mutual recognition agreements (MRAs) of professionals and skilled services, so that if they approve our nursing colleges then the nursing degree from that college will get automatic recognition here and vice versa, he said. On the other hand, India has offered significant concessions on goods of export interest to the UAE and that include dates, petroleum products (crude, LPG, Naptha), petrochemicals (polyethylene, polypropylene and poly vinyl chloride), metals (aluminium, copper, nickel, iron and steel), minerals (limestone, cement).

India will be giving duty-free access to 7,694 goods on the day of implementation of the agreement. Around 2,400 goods would get zero duty in 5-10 years time period.

As part of protective measures in the pact, there are stringent rules of origin criteria that reflect the requirement for substantial processing of up to 40 per cent for most of the products and wholly obtained criteria for agricultural products.

When asked about free trade agreement with the Gulf Cooperation Council (GCC), Goyal said: we are at an advanced stage of discussion on the scope of the agreement. I believe that discussions will get over in the next 15-20 days.

Source: Millennium Post, 28.03.2022



US Pharmacopeia to invest in PCM lab in Genome Valley

Hyderabad: The Telangana government on Sunday said United States Pharmacopeia (USP), that formulates standards for medicines, food ingredients & dietary supplements, will be setting up a new continuous manufacturing (flow chemistry) facility in Hyderabad at an investment of \$200,000 that will help pharmaceutical manufacturers gain efficiencies and flexibility in manufacturing processes.

The new laboratory spread over 12,500 sft with a team of over 50 scientists will support development of guidelines for new processes and technologies in the area of continuous manufacturing processes.

The announcement was made during the meeting of a delegation led by Telangana IT and industries minister KT Rama Rao with its senior officials comprising of Stan Burhans, chief finance officer, USP-US and head of USP India operations and KV Surendra Nath, Senior Vice-President, regions (strategy and operations), USP, in the US.

USP India has invested more than \$ 5 million in the last 24 months towards the development of infrastructure and capital equipment for scientific laboratories and has added more than 70 employees.

Burhans said: “This continued investment in the facility in Hyderabad allows us to reinforce our conviction in life science, support the pharmaceutical industry and promote

public health. We anticipate that India and Hyderabad will further cement its position in the global life sciences arena in the post pandemic world.” At the Genome Valley in Hyderabad, USP India’s operations are spread over 1 lakh sft area with lab capabilities and pharmaceutical certification (verification) programmes.

Source: Times of India, 28.03.2022



Shanghai lockdown may choke pharma supplies

India’s pharmaceutical industry is fearing disruption in Active Pharmaceutical Ingredients (APIs) and intermediates’ supply chains as new Covid lockdown hits Chinese ports. China has imposed a phased lockdown to curb Covid outbreak, causing cargo delays at its two main ports - Shanghai and Shenzhen.

“Cargo operations are disrupted in Shenzhen. The lockdown in Shanghai, which is also home to the world’s largest container shipping port, will further result in cargo delays in days to come,” said an industry expert.

People in the pharma industry say the lockdown of Shanghai which has been announced this week has prompted further fears of disruption in the pharmaceutical supply chain.

“If the shipments remain on hold, cascading effects on the supply chain will be seen. Bulk drug prices and packaging costs have already gone up,” said RC Juneja, executive chairman, Mankind Pharma, one of the leading pharma companies.



India, the world’s third largest drug producer by volume, imports 70% of its requirement of raw materials or intermediates from China. Raw materials from China are used in making major antibiotics, paracetamol, diabetes and cardiovascular drugs.

Domestic companies such as Lupin, Sun Pharmaceuticals, Glenmark, Mankind, Reddy's, Torrent, Aurobindo Pharma, Abbott and several other companies are hugely dependent on Chinese imports. “About 90 per cent of the antibiotics requirement of India is fulfilled by China. The entire spectrum of the industry is going to get impacted if the lockdown continues,” said an expert from a pharma advocacy group, requesting anonymity.

Dinesh Dua, past chairman, Pharmaceuticals Export Promotion Council (Pharmexcil) and co-chairman, CII, North India, says he foresees supply constraints if the lockdown continues as only 20-30% material comes by cargo flights and 70% percent comes by ship. Dua said it’s expensive to get the material by air. “The difference per kilo is 5-10 dollars between air and ship. Container availability is becoming a major problem and this could lead to shortages of medicines and have an impact on exports,” Dua said. Adding that the pharma industry has already started getting feelers from suppliers about supply issues.

“A lot of cargo comes from Shanghai. Shenzhen was already under trouble, If this is not sorted it will make it very difficult for the pharma industry. The logistics cost is going to go further up. Ships, containers are not going to be available. It’s going to impact the pharma industry for sure,” he added. India gets over 70 % of intermediates and is largely dependent on China for APIs imports. Bulk drugs or active pharmaceutical ingredients (APIs) are the raw materials used for making formulations or medicines including essential items like antibiotics, vitamins and folic acid. Intermediates, are chemical compounds that are used in producing APIs.

India is dependent on China for all major essential medicines like paracetamol, Anti acid (ranitidine), Cardiovascular drugs (Sartans), anti diabetes drugs (metformin), antibiotic (ciprofloxacin, ofloxacin), Vitamins (ascorbic acid), acetylsalicylic acid (aspirin), among others. Mehul Shah, a pharma expert familiar with the Chinese pharmaceutical industry said companies cover themselves with extra inventory. However, there is a fear of disruption if the Covid situation doesn’t improve in China.

“At present there is no shortage. We are facing slight delays in getting shipments but uncertainty looms large as the shipments are affected,” Shah added.

Source: Economic Times, 30.03.2022



Local manufacturing of 35 APIs started after PLI scheme: Mandaviya

Manufacturing of 35 active pharmaceutical ingredients, which have been imported earlier, has started in India under the production linked scheme for the pharmaceuticals sector, Union minister Mansukh Mandaviya said on Tuesday. These 35 active pharmaceutical ingredients (APIs) are among the 53 APIs, for which India has 90 per cent import dependence. "The 35 APIs are being manufactured from 32 different manufacturing plants. This will give a boost to AatmaNirbhar Bharat," Mandaviya, the Minister of Health & Family Welfare and Chemical and Fertilisers, told reporters here. This would lead to reduction in import dependence of the key raw materials used for producing medicines, he added.

He said there has been a good response from the pharma industry to the PLI scheme and manufacturing of the other APIs is also expected to start in India in due course of time.

Last year, the government had announced the Rs 15,000 crore PLI scheme for the pharmaceutical sector and 55 companies, including Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy's Laboratories, Lupin, Mylan Laboratories, Cipla and Cadila Healthcare, had qualified for incentives under the scheme.

The incentives are to be paid for a maximum period of six years to each qualified company depending upon the threshold investments and sales criteria achieved by the applicant. The products covered under the scheme include formulations, biopharmaceuticals, active pharmaceutical ingredients, key starting material, drug intermediates, and in-vitro diagnostic medical devices, among others.

According to the government, the objective of the PLI scheme is to enhance India's manufacturing capabilities by increasing investment and production in the pharma sector and contributing to product diversification to high value goods in the pharmaceutical sector. Also, it aims "to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains".

China is the world's largest producer and exporter of APIs and many of the Indian companies depend on imports of the ingredients to produce formulations.

Source: Economic Times, 30.03.2022



Dr Shrenik Shah elected chairman of IDMA Gujarat; plans three-pronged strategy to boost Gujarat pharma sector



Prior to the annual general body meeting (AGM) of the Indian Drug Manufacturers' Association (IDMA) in Mumbai on April 14 and 15, the Gujarat state board of the IDMA (IDMA GSB) has elected the dynamic pharma industrial visionary and managing director of Montage Laboratories Pvt Ltd, Dr. Shrenik Shah, as chairman of the state board for the next two years.

He was serving as the senior vice-chairman of the association from the year 2020. Prior to that, he was the honorary secretary of IDMA GSB for four years from 2017.

According to sources from the state board, the general body of the Gujarat branch was conducted last week mainly to constitute a new administrative body for IDMA GSB which will have a major role in organizing the AGM of the IDMA in Mumbai on April 14 and 15. The body of the new office-bearers can continue upto December 2023.

In an online interview with Pharmabiz, Dr. Shrenik Shah presented a new roadmap for IDMA GSB with focus on the development of the MSME sector. Highlighting his three-pronged strategy to boost the pharmaceutical sector of Gujarat in three letters, 'B-I-G', Dr. Shah said they are his goals to be achieved in the next two years and they stand for Business development, Integration and GMP compliance. The association wants to bring all manufacturing units into one common platform for closer contacts and design strategies to address each one's problems. About ninety percent of the manufacturers come under the MSME sector.

Talking to Pharmabiz, Dr. Shah said, "The pharmaceutical products in Gujarat have the credit of good quality across the country. The association wants to ensure the regulatory standard in all the units for ensuring the pharmaceutical quality through current good manufacturing practices (cGMPs). For this, all units will be updated with the latest regulatory requirements".

For addressing the industry issues, a mobile app has been created, through which every entrepreneur can interact with one another. The app is known as 'Memberly' which denotes 'members' family'.

For developing the idea of integration, monthly meetings and seminars will be conducted in different parts of the state, wherein their issues will also be heard by the state office-bearers and try to solve them by mutual support. In all programmes conducted by IDMA GSB, each member unit will have an equal role and there will not be any regional difference. The integration is mainly indented among the state manufacturers, but gradually everyone will get chances to interact with pharma manufacturers in other states also. Those who want to export their products will get guidance from the association, he categorically said. The state board will work closely with the government authorities for everybody's business growth.

Dr. Shah further said it is a serious concern of the IDMA GSB to strengthen the industry and academia relation for the development of pharmaceutical industry in Gujarat

and to increase job potential for the qualified pharma professionals in the state.

According to him, his association has membership strength of 360 pharmaceutical companies, out of which the major players are Cadila Healthcare Ltd, Torrent Pharma Ltd, Corona Remedies Pvt. Ltd, Troikaa Pharma, Eris Life Sciences Ltd, Saga Lifesciences Ltd, Montage Laboratories Pvt. Ltd, Halewood Laboratories Pvt. Ltd, Stallion Laboratories Pvt. Ltd, Elysium Pharmaceuticals Ltd and Astral Steritech Ltd.

Other office-bearers elected for 2022 and 2023 period are Sanchit K Chaturvedi (sr.vice chairman), Jaya D Patel (VC), Vijay Shah (VC), Sumit J Agrawal (Hon. secretary), Jinkal Patel (Hon. jt secretary), Maulik A Shah (Hon. Jt. Secretary) and Atul J Shah (Hon. treasurer).

Source: Peethaambaran Kunnathoor, Pharmabiz, 31.03.2022



NOW AVAILABLE ! IDMA-APA GUIDELINES / TECHNICAL MONOGRAPHS

TECHNICAL MONOGRAPH NO. 1
**STABILITY TESTING OF EXISTING
DRUGS SUBSTANCES AND PRODUCTS**

TECHNICAL MONOGRAPH NO. 3
**INVESTIGATION OF OUT OF
SPECIFICATION (OOS) TEST RESULTS**

TECHNICAL MONOGRAPH NO. 5
**ENVIRONMENTAL MONITORING
IN CLEANROOMS**

TECHNICAL MONOGRAPH NO. 7
DATA INTEGRITY GOVERNANCE

TECHNICAL MONOGRAPH NO. 2
**PRIMARY & SECONDARY CHEMICAL
REFERENCE SUBSTANCES**

TECHNICAL MONOGRAPH NO. 4
**PHARMACEUTICAL PREFORMULATION
ANALYTICAL STUDIES**

TECHNICAL MONOGRAPH NO. 6
**CORRECTIVE/PREVENTIVE ACTIONS
(CAPA) GUIDELINE**

TECHNICAL DOCUMENT NO. 8
**QUALITY 4.0 DIGITAL TECHNOLOGY
OF THE FUTURE**

Copies are available at IDMA Office, Mumbai. We do not mail any publications against VPP payment. All payments to be made in advance as Cheque/DD/RTGS/NEFT in favour of "INDIAN DRUG MANUFACTURERS' ASSOCIATION" at Mumbai.

For more details please contact: **PUBLICATIONS DEPARTMENT** Tel.: 022 - 2494 4624 / 2497 4308 Fax: 022 - 2495 0723
E-mail: publications@idmaindia.com, Website: www.idma-assn.org/www.indiandrugsonline.org



IDMA BULLETIN

PUBLISHED ON 7th, 14th, 21st and 30th of Every Month

ADVERTISEMENT TARIFF

(Effective from 01.11.2017)

Magazine Size: 21.5 cm x 27.5 cm / Print Area: 18.5 cm x 23.5 cm

Position		Rate per Insertion ₹	
		B/W	Colour
Full Page (18 cm wd x 23.5 cm ht)	:	9,000	12,500
Half Page (18 cm wd x 11.5 cm ht) (Horizontal)		5,000	8,500
Half Page (8.5 cm x 23.5 cm) (Vertical)	:	5,000	8,500
Quarter Page (8.5 cm wd x 11.5 cm ht)	:	2,500	6,000
Strips Advts (4 cm ht x 18 cm wd)	:	2,500	-
Inside Cover Pages	:	-	18,000
Back Cover	:		25,000
Centre Spread (double spread) Print area (40cm wd x 27cm ht)	:	25,000	30,000

Terms and Conditions:

- All payments by **Cheque/ Demand Draft/RTGS** in advance only to be made in favour of “**Indian Drug Manufacturers’ Association**”, Payable at Mumbai
The RTGS details are as follows:- BANK: BANK OF BARODA
Account Name : **Indian Drug Manufacturers’ Association, Bank A/c No. : Current A/c 76080200000242**
Bank : **BANK OF BARODA, Branch Address : Worli Branch, Mumbai-18, IFSC : BARB0DBWORL**
MICR CODE : 400012332
- GST will be charged extra, as applicable. (Current Rate is @5%)
- SPECIAL DISCOUNTS for Series Advertisements
- For colour advertisements, positives to be supplied otherwise processing charges to be paid.
- Advertisement material must reach us 7 days before the date of publication.**
- Positioning of the Advt other than Cover Positions will be at our discretion.
- Only Colour Advts will be entertained on Cover Positions.

Classified Advertisements

- Upto 80 words — ₹2,000/-
- 50% extra for Advt Box Number
- 50% extra for indent/layout spacing, bold captions, etc.
- ₹50/- extra for voucher copy
- Series discount not applicable for classifieds

For further details such as series discounts etc, please contact:
Melvin Rodrigues — Cell: +9821868758 (Email: actadm@idmaindia.com)/
Geeta Suvarna — Cell: +9820161419 (Email: publications@idmaindia.com)

PUBLICATIONS DIVISION

INDIAN DRUG MANUFACTURERS’ ASSOCIATION

102-B, Poonam Chambers, Dr. A. B. Road, Worli, Mumbai 400 018. Tel: 022-2494 4624/2497 4308 Fax: 022-2495 0723
Website: www.idma-assn.org/www.indiandrugsonline.org

INFINITE POSSIBILITIES. **ONE FOCUS.**

Dear Partner,

At Signet, we have always been led by passion. And focus. Our two guiding principles that have today made us the "first recall" name and the market leader in the high quality pharmaceutical excipients industry in India.

Today, as we enter a new decade, we consider it our privilege to renew our pledge to serve our principals and customers in the same way we have been for the last 36 years.

With rigorous knowhow and deep dedication. Because while the world of possibilities is infinite, our focus is on just one.

You.

Signet-ure
focus

Signet

The Complete Excipients Company



Turning helpless into help



Unit Dose System, the single shot nasal drug delivery device from Aptar Pharma

You may recognize our UDS as the delivery device for NARCAN[®], the first and only FDA-approved nasal form of Naloxone, used for the treatment of an opioid emergency. What you may not recognize is that there is so much more to this device than just for emergency situations.

UDS was designed to enable the systemic delivery of drugs without the need for injection or administration by a healthcare professional. Primeless, with one-handed actuation and 360° functionality, this device is approved with multiple drug products by the FDA and is used by thousands of people every day in a range of scenarios from migraine medication through to breakthrough pain relief in end-of-life situations.

All delivered with the certainty of science and safety you'd expect from Aptar Pharma, one of the world's leading providers of drug delivery systems.

To find out more about how Aptar Pharma can help you make a positive impact on patients' lives, call **Herve Pacaud**, Business Development Director at Aptar Pharma on **+33 1 3917 2020** or email **herve.pacaud@aptar.com**



Delivering solutions, shaping the future.

Aptar
pharma